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°C Degrees Celsius
µg Micro gram
µl Micro liter
Å Ångstrøm
aa Aminoacids
Ab Antibody
app. Approximately
Asp Aspartate
ATM Ataxia telangiectasia protein M
ATP Adenosine triphosphate
bp Base pair
cpm Counts per minute
CPT Camptothecin
Da Dalton
DMS Dimethylsuberimidate
DMSO Dimethyl sulphoxid
DNA Deoxyribonucleic acid
DNA-PK DNA-dependent protein kinase
DTT Dithiotreitol
EDTA Ethylendiamin-tetra-acetic acid
F Phenylalanine
FPLC Fast protein liquid chromatography
g Gram or gravity
His Histidine
hr. Hour
HRP Horse-radish-peroxidase
hrs. Hours
htopo70 Human topoisomerase I 70 kDa
truncation mutant
htopoI Human topoisomerase I
ICT In vivo crosslinked topoisomerase
vk Kilo
M Molar
m Murine
Mdm2 Mouse double minute 2 protein
mg Milli gram
min Minute
ml Milli liter
mm Milli meter
mM Milli molar
NER Nucleotide excision repair
ng Nano gram
Ni Nickel
NLS Nuclear localisation signal
nt Nucleotide
nts Nucleotides
OL Oligomer
p53 Tumor suppressor protein p53
PAGE Polyacrylamide gel electrophoresis
PCNA Proliferating cell nuclear antigen
PCV Packed cell volume
PMSF Phenylmethylsulfonylflourid
PVDF Polyvinylidenfluorid
Rb Retinoblastoma protein
rDNA DNA stretch coding for ribosomal
RNA.
Ref-1 Redox factor 1
RNA Ribonucleic acid
RPA Replication protein A
rpm Rounds per minute
S Serine
SDS Sodium dodecylsulfate
Ser Serine
SV40 Simian virus 40
vi
TBE Tris-borate-EDTA
Tdp1 Tyrosyl-DNA phosphodiesterase 1
TDP1 Gene encoding for the Tdp1
enzyme
TE Tris-EDTA
topoI Topoisomerase I
Tyr Tyrosine
U Unit
UV Ultra violet light
v/v Volume to volume
vol. Volume
W Watt
w/v Weight to volume
wt Wildtype
XP-A Xeroderma pigmentosum
complementation group A
XPA Xeroderma pigmentosum
complementation group A protein
XP-D Xeroderma pigmentosum
complementation group D
XPD Xeroderma pigmentosum
complementation group D protein
Y Tyrosine
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1 Introduction
Topoisomerases are abundant enzymes that are involved in several important
pathways, such as transcription and replication (Stewart et al. 1987, Yang et al.
1987, Snapka et al. 1988, Stewart et al. 1990) where the removal of positive
supercoils is required for ongoing RNA and DNA synthesis. However, involvement
in recombination and repair has also been suggested (Zhu and Schiestl 1996,
Megonigal et al. 1997, Cheng et al. 1998, Nitiss and Wang 1988, Shcherbakova
and Filatov 2000; Polanco et al. 2000).
1.1 Introduction to topoisomerase I
Topoisomerases are classified into two major groups, type I (A and B) and type II.
Type II enzymes are the prokaryotic topoisomerase IV (Kato et al. 1990, 1992),
DNA gyrase and the eukaryotic topoisomerase IIα and IIβ enzymes. They function
as a homodimer and cleave both strands of the DNA thereby changing the linking
number by two for every catalytic cycle. The catalytic activity is ATP-dependent.
The incision results in a covalent linkage of the enzyme to the 5’ end of each DNA
strand and generates a double-strand break with a free 3’-OH group.
Type I A enzymes cover enzymes from various organisms: among others
Escherichia coli topoisomerase I, yeast and human topoisomerase III (Andersen
et al. 1996, Goulaouic et al. 1999). They are monomeric enzymes which cleave
one DNA strand and change the linking number by one. During the catalytic cycle
they become covalently attached to the 5’ end of one strand and generate a nick
with a free 3’-OH group. Type IB topoisomerases comprise the eukaryotic and
poxvirus topoisomerase I (Andersen et al. 1996) and the prokaryotic
(Methanopyrus kandleri) topoisomerase V (Slesarev et al. 1993). The human
topoisomerase I exists both as a nuclear (htopoI) and a mitochondrial (htopoImt)
enzyme (Zhang et al. 2001) which are encoded for by two separate nuclear
genes. These topoisomerases also cleave one DNA strand and change the linking
number by one without the use of ATP. However, in contrast to type I A and type II
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they form a covalent complex with the 3’ end of one DNA strand generating a nick
with a free 5’-OH group.
1.1.1 Structure of htopoI
HtopoI consists of 765 aa (91 kDa) encoded by the TOP1 gene. Studies from
limited proteolysis and crystal structure determination indicated that htopoI
consists of four distinct domains: a N-terminal domain (aa 1 to 198), a core
domain (aa 198 to 651), a linker domain (aa 651 to 696), and a C-terminal domain
(aa 696 to 765) (Stewart et al. 1996, Stewart et al. 1997, Redinbo et al. 1998).
The N-terminal domain is largely disordered, highly charged and contains very few
hydrophobic residues (Redinbo et al. 1998). It contains four putative nuclear
localization signals (NLS) which also have been shown to be responsible for the
nuclear localization (Mo et al. 2000). Otherwise it is unclear what role the N-
terminus plays, since it is dispensable for the catalytic activity (Stewart et al.
1997). The 54 kDa core domain is resistant to proteolysis. It contains the main
DNA binding domain and, together with the C-terminal domain, forms a closed
clamp around the DNA (Redinbo et al. 1998, Stewart et al. 1998). The core
domain is coupled to the C-terminal domain by a 3 kDa short linker which has
been found to be flexible and to change conformation upon binding and cleavage
(Stewart et al. 1998, Redinbo et al. 1999). The C-terminal domain has a molecular
weight of app. 10 kDa and contains the active site Tyr723 which is responsible for
the formation of the phosphodiester bond to the 3’ end of the cleavage site. The
C-terminal domain is tightly associated with the core domain and remains
associated with the core although the linker domain is cleaved. The minimal
requirement for catalytic activity in vitro is only the core and C-terminal domains.
They retain around 60 to 70% activity compared with wild-type. This was found by
partial proteolysis investigations (Stewart et al. 1996) and by expression of each
domain separately and mixing of the domains in a 1:1 ratio (Stewart et al. 1997).
The crystal structure of htopoI was published by Redinbo et al. (1998) and
Stewart et al. (1998). The structure was solved of a partially reconstituted enzyme
consisting of the core and the C-terminal domain (Redinbo et al. 1998) and also of
htopo70, which only lacks the N-terminal domain (Stewart et al. 1998). The overall
dimensions of the reconstituted enzyme were 70 Å x 60 Å x 60 Å (Redinbo et al.
Introduction
Kent Søe
3
1998). However, in this structure the linker domain is lacking. Stewart et al. (1998)
published the crystal structure of htopo70 and found that it was very similar to the
crystal of the reconstituted enzyme. Furthermore, in this crystal it was possible to
identify the structure of the linker domain. The linker mainly consists of two long α-
helices connected by a short turn in an antiparallel coiled-coil structure. This
structure is very stable, but the position in respect to the core and C-terminal
domains may vary considerably (Redinbo et al. 1999).
When bound to DNA the core and C-terminal domains form a closed clamp
structure around the DNA with a diameter of the cavity of approximately 20 Å. The
inner surface of this clamp has a high positive charge that mediates a strong
binding to DNA. The enzyme contacts the DNA 4 bp upstream and 6 bp
downstream of the cleavage site, with only a single base-specific contact one
base upstream of the cleavage site on the scissile strand (Redinbo et al. 1998). At
this site there is a preference for a thymidine, which also correlates with studies of
preferred cleavage sites in vitro (Kjeldsen et al. 1988).
1.1.2 Catalytic mechanism of htopoI
On the basis of the information gained from the crystal structures a model for the
catalytic cycle was set up by Stewart et al. (1998). This model is shown in a
simplified version in Figure I. A. HtopoI is in an open clamp state, possibly by a
hinge-bending within the core domain. B. HtopoI binds the DNA by closing the
clamp completely and thus surrounds the DNA. As a result of these changes in
conformation the active site is brought into the correct position for the nucleophilic
attack on the DNA backbone. C. The nucleophilic attack takes place and the
enzyme is covalently linked to the 3’ end of the DNA. D. Subsequently, the
controlled release of superhelical tension can occur during one or more cycles. E.
Religation takes place and the covalent linkage is broken. F and G. The enzyme
releases the DNA with reduced superhelicity and can start a new cycle.
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Figure I.  Schematic representation of the catalytic cycle of htopoI.
See text for detail. Modified from Stewart et al. 1998.
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1.1.3 Inhibitors of human topoisomerase I used in chemotherapy
In the treatment of several cancer types, such as ovarian cancer and colon cancer
(Armand et al. 1995, O’Reilly et al. 1996, Creemers et al. 1996, Ten Bokkel
Huinink et al. 1997), htopoI can be turned into a cellular poison to kill off the
cancer cells. These clinical achievements are mainly due to the discovery of Wall
et al. (1966). They found that the major anti-tumor alkaloid of the Chinese tree
Camptotheca acuminata was an aromatic compound which they named
camptothecin (CPT). The early clinical trials were aborted due to toxic side effects
(Pommier, 1998). However, during the past years a whole family of camptothecin
derivatives has been developed.
        
Figure II. Inhibitory function of CPT. HtopoI binds and cleaves the
DNA and transiently forms a cleavage complex. This complex can be bound
by CPT, which blocks the free 5’-OH necessary for religation from entering the
active site and thereby causes a reversible stabilization of the cleavage
complex.
Camptothecin drugs all function as specific topoisomerase I poisons. They
cause the stabilization of the covalent state of the htopoI catalytic cycle where the
enzyme is covalently bound to the DNA, which is also called the cleavage complex
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(Figure II). This stabilization is reversible when the drug is removed from the
solution. The stabilization of the protein-DNA complex generates a long lived
single strand nick. In the normal catalytic cycle this nick occurs only transiently,
but in the presence of CPT the nick is persistent. These persistent nicks have
been shown to be converted into double-strand breaks. At the same time it has
also been shown that the degree of double-strand breaks introduced correlates
with cell death (Ryan et al. 1991, Squires et al. 1991, Squires et al. 1993). By
treating cells with CPT and aphidicolin at the same time it was seen that no
double-strand breaks were introduced and no cell death was observed (Ryan et
al. 1991). Since aphidicolin inhibits replication, this experiment showed that the
double-strand breaks were a result of replication forks colliding with a htopoI
cleavage complex. The observation that the double-strand breaks correlate with
cell death makes it highly likely that double-strand breaks rather than the covalent
htopoI-DNA complexes alone are responsible for cell death caused by CPT.
1.2 Role of eukaryotic topoI
1.2.1 Knockout studies of topoI
Eukaryotic topoI is an essential enzyme which plays various roles during the cell
cycle and development. It was found by genetic knock-outs in both Drosophila
melanogaster and mouse that topoI is an essential enzyme. In Drosophila
melanogaster topoI-/- larvae died at a very early stage (Zhang et al. 2000) which
also holds for topoI-/- embryos of mice. These embryos could develop to the 4th or
8th cell stage, but failed to enter the 16th (Morham et al. 1996). In both organisms
maternal topoI was present in the egg at the time of fertilization. When this stock
of topoI had decreased to a critical level and no endogenous topoI was expressed
the embryo died. The presence of maternal topoI in the egg underlines the
important role of topoI during development. The importance of topoI is also
deducible from its high degree of conservation during evolution. However,
mammalian cancer cells in culture, which are resistant to CPT and its analogs, are
able to survive although no topoI activity is detectable. This indicates that the
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essential requirement for htopoI can be overcome in cancer cells (Mattern et al.
1991).
1.2.2 Involvement of topoI in transcription and replication
TopoI has been found to be linked to RNA polymerase II transcribed genes. This
has primarily been found by treating cells with CPT and searching for introduced
cleavages within particular genes. Gilmour and Elgin (1987) found topoI cleavage
sites within the heat shock genes in cultured Drosophila melanogaster cells; a
partial inhibition of transcription of the genes by CPT was also observed. Stewart
and Schutz (1987) found in cultured rat cells that CPT-induced topoI cleavages
were located within the tyrosine aminotransferase gene and that the degree of
cleavage depended on the transcriptional activity. In addition they also found a
repression of transcription by CPT. Finally, Stewart et al. (1990) found that the
tightly regulated c-fos gene was cleaved by htopoI in the presence of CPT and
active transcription. However, when transcription of the gene was shut off,
cleavages were no longer detected. TopoI has also been found to be connected to
RNA polymerase I transcription (Brill et al. 1987, Rose et al. 1988).
All of the aforementioned works show that topoI plays an important role in
transcription, but what is its function? Tsao et al. (1989) found that transcription of
a gene inserted into a plasmid could be inhibited by the addition of E. coli topoI in
vitro. Prokaryotic topoI only removes negative supercoils. On a normal plasmid
positive and negative supercoils can eliminate each other in vitro by rotation.
When the negative supercoils are selectively removed, positive supercoils
accumulate. Since this was found, it can be concluded that transcription
introduces positive supercoils downstream of the polymerase and negative
supercoils upstream of it. Tsao et al. (1989) and Gartenberg and Wang (1992)
found that eukaryotic topoI is important for ensuring full length transcripts by
removing the supercoils. Therefore topoI cleaves at distinct sites within the RNA
polymerase II transcribed genes to ensure the formation of full length transcripts.
Besides the involvement in transcription topoI has been found to take part
in DNA replication. TopoI was found to bind specifically to the Simian virus 40
(SV40) large T-antigen double hexamer in vitro (Gai et al. 2000) and to be directly
involved in the removal of supercoils during SV40 replication in vitro (Tsao et al.
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1998, Snapka 1986) as well as in vivo (Snapka et al. 1998). In addition it has been
found to interact with the important replication factor PCNA (Loor et al. 1997).
PCNA functions as a so called “sliding clamp” and plays a role in the processivity
of DNA polymerase δ and ε.
Since topoI is involved in such important cellular activities it is of crucial
importance. However, since it is an enzyme which transiently inserts a strand
break it could be a potential threat to the cell if this transient state were to be
prolonged. This can be achieved with chemotherapeutics as described above or
when DNA damage is present in the genome.
1.2.3 Linkage between DNA damage and topoI
It has recently been demonstrated that various DNA lesions can increase the
amount of htopoI reversible cleavage complexes (Kingma and Osheroff 1998).
These lesions include abasic sites, oxidative damage, gaps, base mismatches,
methylation, and UV-photoproducts (Lanza et al. 1996, Pourquier et al. 1997a,
Pourquier et al. 1997b, Subramanian et al. 1998, Christiansen and Westergaard
1999, Pourquier et al. 1999, Pourquier et al. 2000, Pourquier et al. 2001). HtopoI
recognizes these lesions, and a reversible covalent complex is formed. It is known
that htopoI preferentially binds DNA which is bent due to supercoils or due to
sequence dependent DNA structures (Krogh et al. 1991). It is thus an accepted
hypothesis that htopoI does not recognize the damage itself, but rather the
disturbance of the double helix which leads to bending. All the aforementioned
mentioned lesions decrease the thermal stability of the DNA double helix and
interfere with base paring which in turn causes bending of the DNA (reviewed in
Kingma and Osheroff 1998, Pourquier and Pommier 2001). The tension of DNA
can be released by an upstream cleavage by htopoI. The close proximity of the
lesion prevents base paring of the 5’ hydroxyl carrying strand and thus inhibits the
religation step. This leads to a stabilization of the cleavage complex (Figure III).
This explanation holds for all the lesions mentioned above with the exception of
oxidative damage, which was found by Pourquier et al. (1999) to stimulate DNA
binding rather than inhibiting ligation. When present prior to DNA replication such
complexes block fork migration and may initiate homologous or non-homologous
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recombination (Nitiss and Wang 1988, Megonigal et al. 1997, Shcherbakova and
Filatov 2000, Polanco et al. 2000). The stabilized cleavage complexes may also
                      
Figure III. Cleavage by htopoI at a DNA lesion. See text for details.
cause genome fragmentation, as has been shown for complexes formed in the
presence of CPT (Ryan et al. 1991, Squires et al. 1991, Shcherbakova and Filatov
2000). Wu and Liu (1997) found that a collision with the transcription machinery
can lead to the formation of irreversible complexes, which pose a great threat to
the survival of the cell. The formation of such complexes in the vicinity of a DNA
lesion have also been shown in vivo (Subramanian et al. 1998, Pourquier et al.
2000, Pourquier et al. 2001). It was suggested by Subramanian et al. (1998) that
the formation of such complexes could be a step in the repair of DNA lesions by
nucleotide excision repair. This was suggested because two nucleotide excision
repair deficient cell lines (XP-A and XP-D) showed a decreased level of cleavage
complex formation by htopoI on damaged DNA. However, this theory has not yet
been confirmed. Rather, Frosina and Rossi (1992) found that htopoI cleavage
complexes inhibited nucleotide excision repair in vitro. It is therefore possible that
cleavage complexes are  bulky lesions that need to be removed. A number of
studies have been carried out to search for a repair mechanism for topoisomerase
I-DNA complexes. Nash and co-workers (Yang et al. 1996; Pouliot et al. 1999)
have identified a tyrosine-DNA phosphodiesterase (Tdp1) in Saccharomyces
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cerevisiae, which can remove the cleavage complex at the bond between topoI
and DNA in vitro, if the cleavage complex was in a denatured state. When the
TDP1 gene was knocked out the cells became somewhat more sensitive to CPT
treatment indicating that this enzyme may be involved in the repair of such a bulky
lesion in yeast. Human DNA sequences which show homology to the identified
yeast gene have also been identified (Pouliot et al. 1999, Interthal et al. 2001).
However, it still remains unclear if this human enzyme is invoved in the repair of
htopoI cleavage complexes in vivo and if so to what extent. Therefore, it is still
unclear how htopoI cleavage complexes are repaired in human cells. This
question thus remains an issue of further interest.
1.2.4 Stimulation of htopoI by the tumor suppressor protein p53
Gobert et al. (1996) found that the activity of htopoI was stimulated by the tumor
suppressor protein p53 in vitro and this was later confirmed by Albor et al. (1998).
Albor et al. (1998) also found that mutant p53 lacking other activities still was able
to stimulate htopoI in vitro. This was also found to be true in vivo (Gobert et al.
1999), and it was furthermore found that p53 was needed in vivo for the
recognition of DNA lesions by htopoI (Mao et al. 2000). These findings have made
it interesting to investigate further what the significance of these htopoI and p53
data could be. This was one of the goals in the work presented here.
1.3 Introduction to the tumor suppressor protein p53
One of the most frequently studied genes in the scientific literature is the p53
gene. The main reason for this interest is due to the observation that
approximately 50% of the major human tumor forms contain mutations in this
gene (Hollstein et al. 1994). This suggested that p53 could be involved in
preventing cancer in one way or the other. In the late 1980’s p53 was suggested
to be a tumor suppressor (reviewed by Ko and Prives 1996). This was confirmed
by the first p53 knock-out mice (Donehower et al. 1992).
Donehower et al. (1992) created a p53 knock-out mouse germ line by
homologous recombination into exon 5 of the murine p53 gene in embryonic stem
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cells. In this way chimeric mice heterozygous for the p53 gene were generated.
These were crossed and in the litter a distribution of homozygous wild-
type:heterozygous:homozygote p53 negative of 1:2:1 was observed showing that
the hetero- as well as the homozygote embryos were viable. However, after 6
months a clear difference between the litter mates was observed. 74% of mice
that were p53-/- had developed cancer within the first 6 months whereas 20% of
the heterozygotes (p53+/-) went on to develop cancer within 18 months after birth.
Only 2% of the wild-type litter mates developed cancer after 14 months. In another
study by Lebel et al. (2001) it was found that approximately 50% of p53 null mice
developed cancer within 5 months which correlated very well with the results of
Donehower and co-workers (1992). A lot of work demonstrates that p53 is a tumor
suppressor protein and it has therefore been important to find out how and why
this function is manifested. As mentioned above many scientists have been
working on this problem for several decades and a long list of possible answers
has been given. However, still many questions remain and the present thesis is
also thought to address some of these, but this will be discussed in more detail
later.
In order to give an overview of the functions which have been found for
p53, different issues will be dealt with separately in the following sections.
However, due to the enormous amount of information in this field only the issues
which are most relevant to this thesis will be presented.
1.3.1 Regulation of p53
p53 has been found to be a tetramer and tetramerization is mediated through the
aa 320-360 located in the C-terminal domain (Stürzbecher et al. 1992). This
tetramer can function as a transcriptional activator of several genes involved in the
regulation of the cell cycle and/or apoptosis. However, this activity is only useful
upon genotoxic stress and it is therefore kept under tight control. One of the main
mechanisms to regulate p53 appears to be mediated through the MDM2 protein.
p53 physically forms a complex with MDM2 whereby it becomes inactivated as a
transcription activator and is targeted for degradation (Oliner et al. 1993, Kubbutat
et al. 1997). In addition, free p53 tetramer is able to transcriptionally activate the
MDM2 gene in a negative feedback loop (Wu et al. 1993).
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When a cell is exposed to genotoxic stress, however, the level of free p53
increases. Upon DNA damage p53 is phosphorylated at Ser15 (Siliciano et al.
1997) possibly by the ATM gene product (Siliciano et al. 1997, Banin et al. 1998).
This leads to the dissociation of the MDM2/p53 complex (Shieh et al. 1997) and
thereby to a stabilization of p53 and an increase in the concentration of p53. Once
upregulated, p53 has been suggested to induce various pathways, which finally
lead to cell cycle arrest and/or apoptosis, although many details of these pathways
are still unclear.
1.3.2 p53 in cell cycle arrest
p53 has been shown to function as a transcriptional activator of several genes
after genotoxic stress. One of the most well studied genes is the p21WAF1 gene,
which encodes a cyclin-dependent kinase inhibitor. P21WAF1 prevents the
phosphorylation of the Rb protein in complex with the growth factor E2F, and E2F
can therefore not be released from the complex which leads to G1-arrest
(reviewed by Albor and Kulesz-Martin 2000). P21WAF1 has also been shown to
inhibit PCNA-dependent DNA synthesis and thereby blocks ongoing DNA
synthesis when the DNA is damaged (Waga et al. 1994, Li et al. 1994). The
aforementioned negative feedback regulation of p53 (chapter 1.3.1) ensures that
the induction of cell cycle arrest only takes place after genotoxic stress (either
transiently or permanently).
The example mentioned above is one of the most studied pathways in
which p53 can induce G1 arrest. There seem, however, also to be other functions
of p53 besides the transactivator activity that is involved in the induction of cell
cycle arrest. Jaks et al. (2001) found that when exposing cells to low
concentrations of CPT there was a minimal increase in p53, that was however
sufficient to activate the p21WAF1 and MDM2 genes, although, surprisingly, cell
cycle arrest was not induced. When higher concentrations of CPT were used, the
p53 level rose several-fold and induced transcriptional activation of its target
genes and induced cell cycle arrest. These data suggest that the transcriptional
activation of p21WAF1 alone is not sufficient to induce cell cycle arrest, but that the
p53 concentration also has to exceed a certain threshold value.
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1.3.3 p53 in apoptosis
Besides induction of a cell cycle arrest as a response to DNA damage p53 is
believed also to induce apoptosis, if the stress signal is very strong or persistent.
However, to a wide extent it is not known how this function is exerted by p53. The
drug CPT can selectively kill cancer cells by inducing apoptosis. This induction of
apoptosis is p53-dependent (Yang et al. 1996b, Li et al. 1998, Wang et al. 1999).
Some studies have shown that the transactivation of the BAX gene is important for
p53-dependent apoptosis (Zhan et al. 1994, Miyashita and Reed 1995). Bax can
initiate apoptosis by binding to Bcl-2. Bcl-2 is bound to the cytoplasmic face of the
mitochondrial outer membrane. Here it binds the caspase activator Apaf-1. When
Bax binds to Bcl-2, Apaf-1 is released from the complex with Bcl-2 and in turn
activates an apoptotic caspase pathway (Reviewed by Adams and Cory 1998).
Bax may also induce apoptosis independently of Bcl-2 (Knudson and Korsmeyer
1997), possibly by forming pores in the mitochondrial membrane and thereby
inactivating these, which eventually leads to cell death (reviewed by Green and
Reed 1998). Despite this it has also been found that bax-/- mice are still able to
undergo tissue specific apoptosis as a response to γ-irradiation. So Bax appears
not to be absolutely essential for apoptosis (Brady et al. 1996).
Apparently there are also pathways by which p53 can induce apoptosis
without a transactivation of genes. Haupt et al. (1995) found that HeLa cells with a
mutant p53 lacking the ability to transactivate genes still could undergo apoptosis.
This is supported by the observation that MDM2 can inhibit p53-dependent
apoptosis in some cell lines (H1299), but not in others (HeLa). It therefore appears
that there must be alternative pathways to p53 transactivation-dependent
apoptosis.
Thus, to a large extent it still remains a puzzle how p53 induces apoptosis.
The present thesis also tries to shed more light onto this issue.
1.4 Working hypothesis
The fact that htopoI can be trapped in the vicinity of various DNA lesions makes it
very interesting to investigate the pathological significance of these complexes
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and  how cells deal with such a complex formation. It is known that CPT induced
htopoI cleavage complexes are poisons as described above. In the presence of
CPT, non-tumorgenic cells can survive the treatment by going into cell cycle
arrest. When the drug is removed from the blood, the complexes vanish, most
likely because the ligation function of htopoI is restored. However, in the case of
cleavage complex formation at DNA lesions, the complexes cannot immediately
be released and must pose a great threat to the cell. Despite the presence of
these complexes the cells appear to survive, which makes it tempting to speculate
that these complexes are repaired by an as yet unknown mechanism.
I previously investigated whether nucleotide excision repair (NER) could
remove a htopoI cleavage complex in an in vitro assay. The result was that NER
could not remove the lesion. We therefore wished to continue the search for a
possible repair pathway using in vitro assays. In addition we were interested in
investigating whether the tumor suppressor protein p53 could be involved in such
a putative repair pathway, since the action of p53 had been shown to be
connected to the action of htopoI in vitro as well as in vivo.
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2 Materials
2.1 Oligonucleotides
All used oligonucleotides were synthesized by DNA technology, Aarhus, Denmark.
Name Sequence 5’ to 3’
OL1 AAAAAAAGACTTAGA
OL2 TTTTTTTTTTTTTTTTTTCTAAGTCTTTTTTTGCCTTCGCCCG
GATCCCCGCCAAGCTTACCTGCCCTTTGGGCAGGTAAGCT
TGGCGGGGATCCGGGCGAAGGC
OL3 AGAAAAAAAAAAAAAAAAAAGGATCCCCGGAGTGAATTCG
GCCCCTTTGGGGCCGAATTCACTCCGGGGATCC
2.2 Baculoviruses
Name Reference
wt htopoI Stewart et al. 1998
Y723F htopoI A generous gift from Dr. Philippe Clertant, Nice, France
human p53 Bischoff et al. 1990
murine His p53 Wang et al. 1993
bovine p53 A generous gift from Dr. Hella Hartmann, IMB, Jena
2.3 Cell lines
Name Description
High Five Cell line from Trichoplasia ni 5B1-4 ITC Biotechnology,
Heidelberg, Germany
Sf9 Cell line from Spodoptera frugiperda
ovaries
ATCC-number: CRL-
1711
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2.4 Cell culture media
Name Source
TC-100 Biowhittaker, Belgium
Fetal Calf Serum GibcoBRL
2.5 Commercial enzymes
Type Specific activity Source
T4 polynucleotide kinase 10,000 U/ml New England
BioLabs
T4 DNA ligase 400,000 U/ml New England
BioLabs
Proteinase K 5.0 DMC U/mg Serva, Heidelberg
Trypsin 110 U/mg Roche
Subtilisin 5 U/mg Roche
Lysozyme 130,000 U/mg Roche
2.6 Antibodies
The polyclonal rabbit-anti-htopoI antiserum was made by Bioscience, Göttingen
from 500 µg purified htopoI with one primary injection and two booster shots.
The polyclonal sheep-anti-human p53 antibody Ab7 was purchased from
Calbiochem.
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3 Experimental Procedures
3.1 Preparation of recombinant protein
3.1.1 Recombinant wild-type and mutant Y723F human topoisomerase I
The htopoI expressed in Saccharomyces cerevisiae was a generous gift from Dr.
Michael Lisby, Aarhus University, Denmark, and was purified by Ni-column and
Heparin as described in Lisby et al. (1998). Storage was at -20°C in 5 mM Tris-
HCl, 170 mM NaCl, 50% glycerol, pH 7.5, 0.5 mM DTT, 0.5 mM EDTA.
HtopoI expressed in the baculovirus system (both wild-type and mutant) was
purified in the following way. The HiV insect cells were infected with the wild-type
htopoI baculovirus clone or Y723F htopoI (when the tissue culture flasks were 3/4
full) for 48 hrs at 27°C. They were harvested by centrifugation at 220 g, and
followingly redissolved in four packed cell volumes (PCV) lysis buffer. The cells
were homogenized using a Dounce Teflon homogenizor (20 strokes) and
afterwards four PCV Sucrose/glycerol buffer was added. 1 PCV of saturated
ammonium sulfate (pH 7 at 4°C) was added drop wise and allowed to rest for 30
min on ice. The solution was spun for 3 hrs at 35000 rpm at 4°C using a Beckman
SW40-Ti rotor. The pellet was discarded and 4 volumes (of supernatant) saturated
ammonium sulfate was added to the supernatant and left on ice for 30 min The
precipitate was spun down and redissolved in Ni-wash buffer (42x the vol of the
ammonium sulfate pellet). The solution was loaded on a 1 ml pre-equilibrated Ni-
NTA Agarose column (Qiagen) and subsequently washed with Ni-wash buffer.
Topoisomerase I was eluted with 10 vol Ni-elution buffer and collected in fractions.
The fractions were analyzed according to Bradford (1976) and by SDS-PAGE.
The selected fractions were pooled and loaded on a pre-equilibrated 1 ml
Resource Q column (Amersham Pharmacia) by the use of a FPLC (Amersham
Pharmacia). HtopoI does not bind to the column and was collected. The selected
fractions were stored at -20°C in storage buffer.
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Lysis buffer: 
10 mM Tris-HCl, pH 8.0
1 mM EDTA pH 8.0
5 mM DTT
1 mM PMSF
5 mM leupeptin
1% aprotinin
Ni-elution buffer:
30 mM Hepes-KOH, pH 7.9
150 mM NaCl
250 mM imidazole, pH 8.0
10% glycerol (v/v)
1 mM β-mercaptoethanol
1 mM PMSF
Sucrose/glycerol buffer:
 50 mM Tris-HCl, pH 8.0
10 mM MgCl2
25% sucrose (w/v)
50% glycerol (v/v)
2 mM DTT
Storage buffer:
15 mM Hepes-KOH, pH 7.8
          170 mM NaCl
0.5 mM DTT
0.5 mM EDTA pH 8.0
50% glycerol (v/v)
Ni-wash buffer:
30 mM Hepes-KOH, pH 7.9
150 mM NaCl
20 mM imidazole, pH 8.0
10% glycerol (v/v)
1 mM β-mercaptoethanol
1 mM PMSF
3.1.2 Preparation of recombinant p53
Human wt, murine His-tagged, and bovine wt p53 were purified as follows. HiV
insect cells (ITC Biotechnology, Heidelberg) were infected with either one of the
above mentioned baculovirus clones (when the tissue culture flasks were covered
to 3/4) for 48 hrs at 27°C, harvested by centrifugation, and resuspended in 4 pellet
volumes lysis buffer I for the His-tagged murine p53. In the case of the untagged
human and bovine p53, lysis buffer I without imidazole was used. The cells were
lyzed using a Dounce Teflon homogenizor, spun at 48000 g, and the crude extract
was loaded on a pre-equilibrated column.
Murine His-p53 crude extract was loaded on a 1 ml Ni-NTA Agarose
(Qiagen) pre-equilibrated in wash buffer I, washed, and eluted with elution buffer I.
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The protein- rich fractions were identified according to Bradford (1976), pooled,
and loaded on a 1 ml phosphocellulose column (P11, Whatmann) pre-equilibrated
in wash buffer II using FPLC (Amersham Pharmacia). The column was washed,
and eluted with elution buffer II. The fractions were analyzed according to
Bradford (1976) and by 10% SDS-PAGE. The chosen fractions were dialyzed
over-night against storage buffer and stored at 4°C.
For the purification of human and bovine wt p53 the crude extract was
sucked on a 20 ml phosphocellulose column (P11, Whatmann) using vacuum,
washed with wash buffer II, eluted with elution buffer II, and analyzed as above.
The chosen fractions were pooled, adjusted to 0.5 M ammonium sulfate, loaded
on a 20 ml HiLoad phenyl-sepharose column (Amersham Pharmacia) pre-
equilibrated in wash buffer III, washed, eluted with elution buffer III, and examined
as above. The chosen fractions were diluted 1:3 in wash buffer IV and loaded on a
1 ml HiTrap heparin-sepharose column (Amersham Pharmacia) pre-equilibrated in
wash buffer IV, washed, and eluted with a linear gradient from 0% to 50% elution
buffer IV. The eluate was analyzed as above and diluted with wash buffer II to
approximately 100 mM KPi. Thereafter, the protein was loaded on a 1 ml
phosphocellulose column as described above, and eluted in a linear gradient from
0% to 100% elution buffer II. The final samples were dialyzed over-night against
storage buffer and stored at 4°C. The purified wt human p53 and bovine p53 was
a generous gift from Dr. Hella Hartmann.
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Lysis buffer I:
20 mM Tris-HCl pH 8
100 mM NaCl
20 mM imidazole
0.5% NP-40
1 mM DTT
1 mM PMSF
1 mM aprotinin
1 mM leupeptin
Wash buffer III:
50 mM KPi pH 7.8
0.5 M (NH4)2SO4
1 mM EDTA pH 8.0
2 mM β-mercaptoethanol
Wash buffer I:
20 mM Tris-HCl pH 8
100 mM KCl
20 mM imidazole
2.5 mM β-mercaptoethanol
Elution buffer III:
50 mM KPi pH 7.8
1 mM EDTA pH 8.0
2 mM β-mercaptoethanol
Elution buffer I:
20 mM Tris-HCl pH 8
100 mM KCl
250 mM imidazole
2.5 mM β-mercaptoethanol
1 mM PMSF
Wash buffer IV:
25 mM KPi pH 7.8
1 mM EDTA pH 8.0
2 mM β-mercaptoethanol
Wash buffer II:
100 mM KPi pH 7.8
1 mM EDTA pH 8.0
2 mM β-mercaptoethanol
Elution buffer IV:
           800 mM KPi pH 7.8
1 mM EDTA pH 8.0
2 mM β-mercaptoethanol
Elution buffer II:
300 mM KPi pH 7.8
1 mM EDTA pH 8.0
2 mM β-mercaptoethanol
Storage buffer:
20 mM Hepes-KOH pH 7.8
50 mM NaCl
0.1 mM EDTA pH 8.0
0.5 mM DTT
10% glycerol (v/v)
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3.2 Purification of DNA substrate (L193s)
1200 pmol OL1 was labeled with 100 µCi [γ-32P]ATP (3000 Ci/mmol, Amersham
Pharmacia), while 1200 pmol OL2 was phosphorylated with non-radioactive ATP
using 2 µl T4 polynucleotide kinase. OL1 and OL2 were precipitated, redissolved
in deionized H2O, and mixed with 1200 pmol OL3 in a total volume of 30 µl ligation
buffer (as delivered by the supplier) with 3 µl T4 polynucleotide ligase and the
mixture was incubated for 3 to 4 days at 4°C. To the ligation mixture 1 volume
sequencing loading buffer was added, heated to 95°C for 5 min, and subsequently
loaded on a 1 mm thick 7% denaturing polyacrylamide gel (SequaGel Sequencing
System, National Diagnostics) 40x20 cm sequencing apparatus (Roth). The gel
was run in TBE at 45 W (Power Pac 3000, BioRad) which resulted in a
temperature of 50°C. The full length band was identified by 5 to 10 min exposure
to an X-ray film (Hyperfilm MP, Amersham Pharmacia), excised, and eluted
overnight (shaking) in 500 µl TE buffer at 37°C. The eluted oligonucleotide was
precipitated by the addition of 1/10 vol 4 M NaCl and 2 vol absolute ethanol over-
night at -20°C, spun at 18,000 g, redissolved, and phosphorylated with 300 µmol
ATP using 1 µl T4 polynucleotide kinase for 30 min at 37°C. The full length
oligonucleotide was precipitated (as described above) and redissolved in 30 µl TE.
This oligonucleotide was called L193s. The function of this is described in the
chapters 4.1 and 4.2.
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2x Sequencing loading buffer: 
           80% (v/v) formamid
 50 mM Tris-borate (pH 8.3)
1 mM EDTA pH 8.0
1% (w/v) Xylen cyanol
1% (w/v) Bromophenol blue
SequaGel Sequencing System:
Concentrate: 25% (w/v) acrylamide
1.3% (w/v) methylene
                      bisacrylamide
50% (w/v) urea (8.3M)
Dilluent:        50% (w/v) urea
Buffer:          50% (w/v) urea
          10XTBE (1 M Tris, 1 M
                     H3BO3, 20 mM EDTA
                     pH 8.3)
TE:    10 mM Tris-HCl, pH 7.5
   1 mM EDTA pH 8.0
3.3 Detection of suicide cleavage by htopoI
3.3.1 Coomassie stained SDS-PAGE
500 ng htopoI was incubated with non-radioactive L193s (corresponding to
approximately 30000, 60000, and 90000 cpm) for 20 min at 37°C in 50% reaction
buffer. The reactions were stopped with protein loading buffer, then incubated for
5 min at 95°C and separated on a 7% SDS-PAGE. Subsequently the gel was
stained with Coomassie – brilliant blue dye.
3.3.2 Western blot
500 ng recombinant baculovirus-expressed htopoI was incubated with non-
radioactive L193s as described above. Following separation on a 7% SDS-PAGE
the gel was transferred onto a PVDF membrane (Immobilon, Millipore) using a
semi-dry transfer blot cell (BioRad) with transfer buffer for 1 hr at 3 mA/cm2.
Subsequently the membrane was blocked for 20 min in CMF-PBS with 5%
skimmed milk. Thereafter the blot was incubated with the rabbit-anti-htopoI
antiserum in a 1:2000 dilution in CMF-PBS with 5% skimmed milk over-night at
4°C. The blot was washed 3x5 min and 1x15 min in CMF-PBS, and thereafter
incubated 1 hr with an anti-rabbit horse-radish-peroxidase coupled secondary
antibody (1:3000 dilution, Amersham Pharmacia) in CMF-PBS with 5% skimmed
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milk. The blot was washed 5x10 min in CMF-PBS, and developed by ECL by
incubating it for 1 min in a 1:1 mixture of solution A and solution B. Subsequently
the blot was exposed on an X-ray film for various periods of time and
subsequently developed.
Reaction buffer:
25 mM Hepes-KOH, 7.9
100 mM KCl
12 mM MgCl2
17% (v/v) glycerol
1 mM EDTA pH 8.0
1 mM DTT
Solution A:
100 mM Tris-HCl pH 8.5
0.4 mM p-coumaric acid
2.5 mM 5-amino-2,3-dihydro-
                       1,4-phthalazinedione,
                       luminol
Transfer buffer:
10% methanol
96 mM glycine
10 mM Tris-base
Solution B:
100 mM Tris-HCl pH 8.5
0.02% H2O2
CMF-PBS:
167 mM NaCl
20 mM Na2HPO4
2 mM KH2PO4
0.05% (v/v) Tween 20
5xProtein loading buffer:
          330 mM Tris-HCl pH 6.8
          5% SDS
          713 mM β-mercaptoethanol
          2.5% (w/v) bromophenol blue
          50% (v/v) glycerol
3.4 Titration with htopoI using L193s as substrate
30,000 to 40,000 cpm L193s (as measured with a Packard 1900 TR scintillator)
were incubated with increasing amounts of yeast-expressed htopoI (as indicated
in the text) for 40 min at 37°C in 20 µl with 50% reaction buffer (concentration in
the reaction mixture: 12.5 mM Hepes-KOH pH 7.9, 6 mM MgCl2, 50 mM KCl, 42.5
mM NaCl, 21% glycerol, 0.5 mM EDTA pH 8.0, 1 mM DTT). The reaction was
stopped by the addition of 0.4% SDS and 125 µg/ml proteinase K, and further
incubated at 37°C for 60 min In some cases each aliquot was split into two
whereafter one fraction was incubated with protease and the other was not. The
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DNA molecules were precipitated by 3 vol 0.6 M LiCl in absolute ethanol. After 30
min on ice the mixture was centrifuged at 18,000 g. The pellet was redissolved in
sequence loading buffer, heated to 95°C for 5 min and analyzed on a 0.4 mm 20%
denaturing polyacrylamide gel (see chapter 3.2). The gels were analyzed using a
phosphorimager (Molecular Dynamics, Storm 860) and quantified using the
software ImageQuant (Molecular Dynamics).
3.5 Comparison of proteinase K- and trypsin digestion
30,000 to 40,000 cpm L193s was incubated with 0 or 500 ng baculovirus-
expressed htopoI in a 10 µl reaction volume in 50% reaction buffer (see chapter
3.4). The reactions were stopped by the addition of a final concentration of 0.4%
SDS and either no protease or 125 µg/ml proteinase K, or by the addition of 80
µg/ml trypsin (no SDS). The samples were subsequently incubated for 60 min at
37°C, whereafter the DNA was precipitated by ethanol/LiCl (see chapter 3.4) and
analyzed on a 14% denaturing polyacrylamide gel and analyzed as above (see
chapter 3.4), but using a 14% denaturing polyacrylamide gel.
3.6 Investigating the effect of camptothecin
30,000 to 40,000 cpm L193s was incubated with 0 or 500 ng baculovirus-
expressed htopoI in a 13 µl reaction volume in 50% reaction buffer for 5 min at
37°C. Subsequently, 2 µl DMSO or CPT dissolved in DMSO was added to the
concentrations indicated and incubated for an additional 15 min at 37°C. The
reactions were stopped as described above (see chapter 3.4). A sample was
taken for SDS-PAGE analysis prior to protease digestion. The analysis was
performed as described above (see chapter 3.4), but using a 14% denaturing
polyacrylamide gel.
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3.7 Influence of the mutant Y723F htopoI on the double cleavage
of htopoI
30,000 to 40,000 cpm L193s was or was not incubated with 500 ng htopoI, and
with the indicated amounts of mutant Y723F htopoI in 50% reaction buffer (see
chapter 3.4) (concentration in the reaction mixture: 15.5 mM Hepes-KOH pH 7.9,
50 mM KCl, 34 mM NaCl, 6 mM MgCl2, 0.5 mM EDTA, 1 mM DTT, 18.5%
glycerol) in 20 µl for 40 min at 37°C. The reaction was stopped with a final
concentration of 0.7% SDS. An aliquot of 2 µl was taken from each sample and
analyzed on a 7.5% SDS-PAGE followed by quantification using a
phosphorimager and the ImageQuant software (Storm 860, Molecular Dynamics,
Amersham Pharmacia). The remainder of each sample was incubated with 1
mg/ml proteinase K for 30 min at 37°C, and treated and analyzed as described in
chapter 3.4, however analyzed on a 14% denaturing polyacrylamide gel.
3.8 Limited proteolysis of htopoI with subtilisin
Two µg of baculovirus-expressed htopoI (4 µl) was incubated with TE (pH 7.5) or
various concentrations of subtilisin (as indicated in the text) diluted in TE (pH 7.5)
in a total volume of 10 µl (6 mM Hepes, pH 7.9, 6 mM Tris-HCl, pH 7.5, 68 mM
NaCl, and 20% glycerol) for 20 min at 25°C. The reaction was stopped by 5 mM
PMSF and the mixture was put on ice. One µg htopoI was analyzed by SDS-
PAGE and Coomassie-staining. The rest was incubated with 30,000 to 40,000
cpm L193s in a reaction volume of 15 µl in 50% reaction buffer (see chapter 3.4)
(13 mM Hepes-KOH, pH 7.9, 30 mM NaCl, 43 mM KCl, 5 mM MgCl2, and 16%
glycerol) for 40 min at 37°C. The reactions were stopped with 0.4% SDS and a
sample was taken for analysis on a 7.5% SDS-PAGE. The rest was incubated
with proteinase K and analyzed as described above.
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3.9 Preparation of competent E. coli and transformation
The Escherichia coli strain BL21 DE3 (Stratagene) was cultured in LB-medium
and made competent according to the CaCl2 method described by Mandel and
Higa (1970).
The transformation with pUC 19 was performed according to Sambrook et al.
(1989).
LB-medium:
10 g/l Bacto-Tryptone
5 g/l Bacto yeast extract
10 g/l NaCl
pH 7 (adjusted with NaOH)
3.10 Purification of supercoiled pUC 19
This procedure differs from standard plasmid purification protocols because for
this work it was very important to have ONLY supercoiled DNA with as few lesions
as possible. This is not achievable through standard procedures.
Following transformation, a single bacterial colony was picked and grown in
500 ml LB medium (see chapter 3.9) shaking over-night at 37°C. The culture was
harvested by 15 min centrifugation at 3000 g at 4°C. The pellet was resuspended
in 100 ml cold STE buffer and spun as before. Followingly, the pellet was
redissolved in 20 ml cold sucrose buffer and subsequently devided into two 50 ml
tubes on ice. In each tube 1.7 ml lysozyme solution was added, mixed gently, put
on ice for 5 min, 1.7 ml 0.5 M EDTA was added, mixed gently, rested on ice for 5
min, and finally 17 ml lysis buffer was added, mixed gently and left on ice for 15
min After this procedure the solution should be highly viscous. The slurry was
spun at 48,000 g at 4°C for 30 min The complete supernatant was poured through
a filter and loaded on a pre-equilibrated NucleoBond PC 2000 column
(Macherey-Nagel) and the plasmid was purified according to protocol of the
supplier.
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The eluted plasmid still contained nicked, linear, and catenated forms. In order to
get only supercoiled plasmids a native linear sucrose gradient was produced. A 10
ml linear gradient sucrose gradient was made from 5% and 25% sucrose
solutions. Up to 100 µg purified plasmid in TE buffer (max. 1 ml) was carefully
loaded on top of the gradient and spun at 30,000 rpm at 4°C for approximately 16
hrs (SW 40 rotor, Beckmann). The gradient was fractionated by inserting a needle
through the bottom of the tube and collected in approximately 20 fractions. A 7 µl
sample was taken from each fraction, mixed with agarose loading buffer and
analyzed on a 0.8% agarose gel in TBE, and then stained with ethidium bromide.
The fractions containing only supercoiled plasmid were pooled, 3 vol absolute
ethanol was added, put at -20°C over-night and spun at 48,000 g at 4°C for 30
min The pellet was redissolved in TE (pH 7.5) and the concentration was adjusted
to 250 ng/µl.
STE buffer:
           0.1 M NaCl
10 mM Tris-HCl pH 8.0
1 mM EDTA pH 8.0
Lysis buffer:  
          50 mM Tris-HCl pH 8.0
62.5 mM EDTA pH 8.0
0.5% Triton X-100
Sucrose buffer:
           25% (w/v) sucrose
50 mM Tris-HCl pH 8.0
0.1 mg /ml RNase A
Sucrose solution:
           5 or 25% (w/v) sucrose
25 mM Tris-HCl pH 7.5
1 M NaCl
5 mM EDTA pH8.0
Lysozyme buffer:
           10 mM Tris-HCl pH 8.0
20 mg/ml lysozyme
6 x Agarose gel loading buffer:
0.25% (w/v) Bromophenol
                              blue
0.25% (w/v) xylene cyanol
30% (v/v) glycerol
3.11 Influence of p53 on htopoI relaxation activity
Recombinant htopoI (as indicated) was incubated with 1 µg supercoiled pUC 19
plasmid (purified as described in chapter 3.10), and the indicated amount of
recombinant human, bovine, or murine his-tagged p53 in 50% reaction buffer (see
Experimental Procedures
Kent Søe
28
chapter 3.4) (19 mM Hepes-KOH pH 7.9, 50 mM KCl, 30 mM NaCl, 6 mM MgCl2,
0.5 mM EDTA, 1 mM DTT, 16% glycerol, and 15 µg/ml BSA) in 20 µl for 5 min at
37°C or 30°C (as indicated). The reactions were stopped by agarose gel loading
buffer and subsequently incubating for 5 min at 95°C followed by placement on
ice. The plasmids were analyzed on a 0.8% agarose gel in TBE and thereafter
stained with ethidium bromide.
3.12 Protease digestion of htopoI for Far-Western analysis
Thirty µg htopoI was incubated with 3.5 µg/ml subtilisin in TE (pH 8.0) in a final
volume of 150 µl for 20 min at room temperature (25°C), and stopped with 5 mM
PMSF.
3.13 Far-Western analysis
Eleven µg of baculovirus-expressed htopoI and 11 µg subtilisin treated htopoI (as
described above) were incubated in sample buffer for 5 min at room temperature.
11 µg of BSA was treated the same way. Proteins were then separated by SDS-
PAGE as indicated. The gel was incubated for 1 h in renaturation buffer and
transferred to a nitrocellulose membrane (Protran, Schleicher and Schuell) in
transfer buffer. Membranes were blocked in TBS/T buffer and 5% skimmed milk
powder for 1 h at room temperature, washed two times for 5 min in TBS/T buffer,
incubated 1 h at room temperature with 12 µg/ml murine His-p53 or BSA in TBS/T
buffer, washed four times for 15 min with TBS/T buffer, and incubated overnight
with the p53 primary polyclonal sheep antibody Ab-7 (Oncogene) (1:3000 dilution)
at 4 °C in TBS/T buffer with 5% milk powder. Membranes were washed four times
for 15 min in TBS/T buffer, incubated 1 h at room temperature with HRP-
conjugated anti-sheep secondary antibody (Sigma, 1:3000) in TBS/T with 5% milk
powder, and detected by ECL (Amersham Pharmacia Biotech) according to the
supplier’s instructions. The Far-Western analysis was kindly performed by Dr.
Hella Hartmann.
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The identification of the N-terminus of the core domain was done as follows:
HtopoI was digested as described in chapter 3.12. The digest was separated on a
7.5% SDS-PAGE and blotted on a PVDF membrane (Millipore). The blot was
stained with Coomassie stained the band of interest was cut out. This membrane
piece was subsequently subjected to Edman degradation (Applied Biosystems
494 Protein Sequencer) to find the N-terminal sequence. The N-terminal
sequencing was kindly performed by Dr. Bernhard Schlott and Anita Willitzer.
Sample buffer:
2.5% SDS
2.5 mM Tris-HCl pH 8.0
100 mM DTT
10% glycerol
0.05% Pyronin T1
Transfer buffer:
10 mM NaHCO3
3 mM Na2CO3
Renaturation buffer:
50 mM Tris-HCl pH 7.5
20% glycerol
TBS/T buffer:
10 mM Tris-HCl pH 8.0
150 mM NaCl
0.1% Tween 20
3.14 Influence of p53 on the htopoI double cleavage reaction
For the titration experiments with murine His-tagged p53, 400 ng of htopoI was
incubated with murine his-tagged p53 as indicated for 10 min at 37°C in 20 µl of
50% reaction buffer. Ten µM CPT or 2 µl DMSO were added 2 min after the
reactions were started. The mixture was treated and analyzed as described in
chapter 3.4, but using a 14% denaturing polyacrylamide gel.
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4 Results
4.1 Sequence, two dimensional structure, and function of the
DNA substrates
In order to investigate whether a htopoI cleavage complex could be removed in
vitro it was crucial to induce a cleavage complex at one particular location on a
DNA substrate. To do this a previously published method by Svejstrup et al.
(1991) was utilized. This method is based on a small DNA substrate which
efficiently traps covalent htopoI/DNA intermediates. A so called suicide substrate,
L193s, was designed, which efficiently trapped a htopoI cleavage complex at only
one position, according to the method of Svejstrup et al. (1990), but in another
design. The complete sequence and two dimensional structure of the DNA
substrate is depicted in Figure 1A. L193s consisted of a 193 nts long
oligonucleotide that folded back onto itself, thereby forming a 92 bp double-
stranded region with a 3 nts long loop at both ends. In the center of the substrate
was a 3 nts long 5’ overhang at a nick. The sequences of the last 3 nts at each
end of the oligonucleotide were identical. Furthermore, a specific 16 nts long
htopoI binding and cleavage sequence (Busk et al. 1987, Stevnsner et al. 1989)
was included in such a way that the nick was located 3 nts 3’ to the htopoI
cleavage site. Cleavage by htopoI at this site became „suicidal“ due to the
presence of a 5’ phosphate next to the cleavage site (see also Figure 1B). Thus,
the presence of the 5’ phosphate prevented ligation and thereby blocked the
release of htopoI after the cleavage reaction had taken place. This stable complex
was designated as “cleavage complex”.
Correct substrate folding was verified by the existence of BamH I cleavage
sites at the positions indicated in Figure 1A (data not shown). Through BamH I
cleavages it was also verified that the suicide cleavage of htopoI took place at the
correct position (data not shown).
The utilized recombinant htopoI preparations were either expressed in
yeast or by the baculovirus expression system and purified to near homogeneity
(Figure 2A and B).
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Figure 1.  Two dimensional structure and complete sequence of
the substrate L193s and schematic outline of the function. A) The htopoI
cleavage site is indicated with an arrow. The radioactive label (32P) is located
on nucleotide 15 (indicated with an asterisk and the base shown in boldface).
BamH I restriction sites are indicated. See text for further details. B) HtopoI
binds to the hexadecamer binding sequence (bold lines) and cleaves the
upper strand forming a covalent phosphotyrosine-linkage with the 4th nt
(numbering as in Fig. 1A) and thus produces an oligomer consisting of 3
bases. The overhang is identical with those 3 bases, therefore, when the
trimer is liberated by htopoI, the 5’ end can hybridize to the complementary
strand and close the gap. Since the 5’ end is phosphorylated, htopoI is
irreversibly trapped.
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Figure 2. Coomassie staining of yeast and baculovirus-expressed
recombinant htopoI. Coomassie staining of a 7.5% SDS-PAGE. A)
Recombinant htopoI expressed in S. cerevisiae, lane 1, ≈ 3µg htopoI. B)
Recombinant htopoI expressed by baculoviruses, lane 1, 200 ng; lane 2, 400
ng; lane 3, 1000 ng; lane 4, 1500 ng. Marker is a 10 kDa ladder and the sizes
of some of the bands are indicated in kDa.
4.2 Detection of htopoI suicide cleavage on L193s
In order to verify that htopoI did indeed cleave L193s suicidally, reactions with
htopoI and L193s were analyzed by SDS-PAGE. As seen in Figure 3A a shifted
protein band can be detected with increasing L193s concentration (compare lane
1 with lanes 2 to 4). Since the htopoI preparation was highly pure (see lane 1) this
shift is likely due to the suicide cleavage and attachment of L193s, which changes
the mobility of htopoI dramatically. However, to show that the shifted protein band
indeed was htopoI the reactionproducts were also analyzed by Western-blotting.
From Figure 3B it can be seen that the shifted protein band in Figure 3A truly was
htopoI which had cleaved L193s. This shows that the substrate works as intended.
In addition it was possible to estimate the ratio between L193s and htopoI. When
considering the results in Figure 3A and B it can be estimated that the molar ratio
between htopoI and L193s was approximately 10:1 respectively (Figure 3A and B
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lane 2). In general, this was the ratio between htopoI and L193s in the following
experiments.
   
Figure 3. HtopoI cleaves L193s suicidally. A. Coomassie staining of a
7% SDS-PAGE. Lane 1, 1 µg htopoI (baculo-virus expressed), 2, 1 µg htopoI
+ 2 µl L193s, 3, + 4 µl L193s, 4, + 6 µl L193s. B. Western blot of a 7% SDS-
PAGE as in A using a polyclonal rabbit-anti-htopoI antibody. The mobility of a
prestained marker is indicated (kDa). The conditions for the reaction shown in
lane 2 correspond to the ratio between htopoI and radioactively labeled L193s
in the forthcoming figures. See text for further details.
4.3 Titration with human topoisomerase I
To investigate whether htopoI could cleave L193s at positions other than at the
suicide cleavage site, L193s was incubated with increasing amounts of yeast-
expressed htopoI (Figure 4) (a generous gift from Michael Lisby, Aarhus
University, Denmark). The reactions were stopped by the addition of 0.4% SDS,
and  htopoI  was  digested  with  proteinase  K. With  increasing  concentrations of
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Figure 4. Titration with recombinant yeast expressed htopoI.
Autoradiogram of a 20% sequencing gel. L193s was incubated with: lane 1,
no htopoI, lane 2, 125 ng, lane 3, 250 ng, lane 4, 500 ng, lane 5, 750 ng, and
lane 6, 1250 ng htopoI for 40 min at 37°C. In all samples the buffer conditions
were identical. Thereafter all reactions were stopped by the addition of 0.4%
SDS and the protein was digested with proteinase K. Letters ”A”, ”b”, ”c”, and
”d” indicate the double bands discussed in the text.
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topoI a cleavage pattern consisting of 4 double bands occurred (lanes 2 to 6).The
double bands were designated by the letters A, b, c, and d, where A represented
the most predominant cleavage site. None of the bands migrated to a position that
precisely fitted the marker; instead they had an intermediate mobility. Since highly
pure recombinant htopoI was used (Figure 2A, lane 1) we assumed that these
bands were due to additional htopoI cleavages of substrates that already had
been cleaved suicidally.
4.4 DNA fragments are protein linked
In order to investigate further, if the observed bands represented DNA fragments
with proteinase K resistant peptides bound to the 3’ end, three parallel
experiments with varying concentrations of yeast-expressed htopoI were
performed. The DNA from the four double bands should still enter the gel without
proteinase K digestion if the DNA fragments had no covalently attached protein
moieties. In contrast, if htopoI was attached to the 3’ end, the DNA would no
longer be able to enter the gel, but remain in the slot.
As shown in Figure 5 (lanes 3, 5 and 7), none of the four double bands
were seen when the proteinase K digest was omitted, indicating that a large
molecule was bound to the DNA fragments. The cleavage frequency depended on
the amount of htopoI added (Figure 5, compare lanes 2 and 4), indicating that
htopoI indeed was responsible for the formation of the double bands.
Furthermore, since four double bands were produced, htopoI must have cleaved
the substrate at several distinct positions just upstream from the radioactively
labeled nucleotide. It is well known that a high concentration of salt shifts the
equilibrium of htopoI from the cleaving to the non-bound state. Thus, if cleavage
was due to htopoI, it should be possible to reverse the cleavage reactions by the
addition of high concentrations of salt. Therefore, one reaction was stopped with
300 mM NaCl and incubated for another 10 min at 37°C prior to the addition of
SDS. The reaction mixture was then divided into two halves, and one portion was
treated with proteinase K (Figure 5, lane 8) whereas the other aliquot was kept
untreated (lane 9). Salt treatment provoked a clear reduction of the band
intensities (compare lanes 6 and 8). For the bands A and c product formation was
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Figure 5. DNA fragments are protein linked. Autoradiogram of a 20%
sequencing gel. L193s was incubated with: lane 1, no htopoI, lanes 2 and 3,
250 ng, lanes 4 and 5, 750 ng, and lanes 6 to 9, 1250 ng yeast expressed
htopoI for 40 min at 37°C. For each concentration of htopoI used, the reaction
mixtures were split into two aliquots and stopped by the addition of SDS (e.g.
lanes 2 and 3). The samples shown in lanes 1, 2, 4, and 6 were incubated
with proteinase K. The samples shown in lanes 8 and 9 were stopped by the
addition of 300 mM NaCl for 10 min at 37°C, divided into two aliquots; the one
shown in lane 8 was incubated with proteinase K. Lettering is the same as in
Figure 4.
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diminished by 60 to 70%, while for the bands b and d a reduction of about 40%
was observed. When the samples were incubated for longer than 40 to 60 min
after htopoI had been added, the intensities of the cleavage products A, b, c, and
d declined, but did not completely disappear (data not shown). A similar effect was
seen with the salt reversal shown in Figure 5, lane 8. This strongly suggests that
htopoI was responsible for these cleavage reactions, since a putative
contaminating endonuclease would be expected to produce an accumulating
number of cuts with increasing incubation time.
4.5 Position of the second cleavage site on L193s
The results from Figure 4 and 5 were further supported by comparing digests
performed with either proteinase K (Figure 6, lanes 1 and 2), trypsin (lane 3), or
                                
Figure 6. Position of the second cleavage. Autoradiogram of a 14%
sequencing gel. L193s was incubated with: lane 1, no htopoI; lanes 2 to 4,
500 ng htopoI for 40 min at 37°C. The reactions shown in lanes 1, 2, and 4
were stopped by the addition of SDS and subsequently aliquots 1 and 2 were
incubated with proteinase K. The reaction shown in lane 3 was stopped by the
addition of trypsin. Lane 4, no protease was added.
Results
Kent Søe
38
without protease treatment (lane 4). In these experiments only band A was clearly
seen, whereas the cleavage sites b, c, and d were too weak to be detected.
Trypsin produced a different digestion pattern (Figure 6, compare lanes 2
and 3). Thus, the double bands produced by proteinase K treatment turned to a
single band when trypsin digestion was employed instead. It has previously been
shown that a complete digest of DNA-bound htopoI with trypsin leaves seven
amino acids bound to the DNA (Christiansen and Westergaard 1999, Svejstrup et
al. 1990). This supports the results from Figure 5 where cleavage by a second
htopoI only occurred on substrates that already contained a suicidally attached
htopoI molecule. The cleavage product, named A*, represented the same
cleavage site as the proteinase K double band A. This shows that proteinase K
digestion yielded a protease-resistant peptide with two different lengths most likely
corresponding to 5 and 6 amino acids, respectively.
For the results shown in Figure 6 baculovirus-expressed htopoI was used.
The fact that the cleavage sites from Figure 4 and 5 were reproduced with a highly
purified htopoI from another source (Figure 2B) strongly supported the view that
htopoI was responsible for the cleavage reaction. In order to identify the precise
location of the cleavage sites we relied on the experimental finding that trypsin
cleavage of htopoI covalently bound to DNA generates a mobility shift of 5 nts in a
14% sequencing gel (Christiansen and Westergaard 1999, Svejstrup et al. 1990).
Since A* had a mobility of 18 nts, the covalently bound DNA fragment must have
been app. 13 nts long. Thus, the incision was estimated to have occurred 13 nts
upstream from the suicidally bound htopoI. Comparable mobility shifts were also
observed for the bands b, c, and d (data not shown). Therefore, it can be
approximated that these bands resulted from cleavages that took place 15, 17,
and 11 nts respectively upstream from the covalently attached htopoI. Since the
radioactive label was placed 12 nts upstream from the suicidal cleavage site, band
d may also have resulted from a fraction of the suicidally cleaved substrates that
were not cleaved at position 3, but instead at position 5 (see Figure 1A for
numbering). It is well known that the majority of htopoI incisions take place at
position 3, but a minor fraction occur at position 5 in the htopoI recognition
sequence which is included in our substrate, L193s (Christiansen et al. 1993,
Christiansen and Westergaard 1994).
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4.6 The second cleavage reaction is sensitive to CPT treatment
To further support the view that the cleavage reaction was caused by a htopoI,
L193s and htopoI were incubated in the presence of the topoisomerase I specific
 
Figure 7. CPT sensitivity of the second cleavage. 500 ng
baculovirus-expressed htopoI was incubated with the suicide substrate in the
presence of DMSO or CPT as indicated. ”C” is without htopoI; ”htopoI” is
htopoI under standard conditions. A) The graphics represents a quantification
(as described in chapter 3.4) of the percentage of suicide cleavage in regard
to the total substrate used (see Experimental Procedures). B) The graphics is
a quantification of the relative effect of DMSO and CPT on the second
cleavage site ”A”. C) Autoradiogram of a 14% sequencing gel showing the
results quantified in B. The results shown are representative for three
independent experiments.
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drug CPT. A titration with CPT was performed and the influence on the suicide
cleavage as well as the cleavage complex specific incisions were tested. CPT
showed no effect on the suicide cleavage (Figure 7A). This, however, is not
surprising since the suicide substrate has the same effect as CPT, namely the
inhibition of the religation step. Therefore, CPT cannot block ligation at the site of
suicide cleavage since religation is already inhibited. In Figure 7B and C the effect
of CPT on the second cleavage reaction is shown. In the presence of CPT up to
app. 12-fold stimulation was observed. However, since DMSO alone also showed
a app. two fold stimulation, the stimulatory effect of CPT may have been at least
six fold. The autoradiogram to Figure 7B indicates that CPT also had a stimulatory
effect on the cleavage sites b and c and to a smaller extent on d (Figure 7C).
These alternate cleavage reactions were rather rare events compared to the
cleavage at position A. In general the double cleavage A had a maximum
efficiency of 12% in the absence of CPT when only taking the suicidally cleaved
DNA into consideration. In the presence of CPT this could be increased up to a
maximum of 35%.
4.7 Active site mutant Y723F htopoI can compete with htopoI
double cleavage
The data shown above bring strong proof that a second htopoI can cleave
specifically upstream from a htopoI cleavage complex. To be absolutely sure that
the second incision is due to an additional htopoI enzyme a titration was done with
purified mutant htopoI. This mutant carries an amino acid exchange of the active
site Tyr723 to Phe. Tyr723 is responsible for the covalent linkage to the DNA
backbone, thus the mutant Y723F htopoI has the same functions concerning
protein interactions, DNA binding etc., but is unable to cleave the DNA. It was
speculated that this mutant htopoI should be able to compete with the second
htopoI cleavage step in a 1:1 ratio, meaning that equal amounts of mutant and wt
htopoI should inhibit the reaction by approximately 50%.
As a control the influence of Y723F htopoI on the suicide cleavage was
tested (Figure 8A). As it can be seen, the mutant htopoI had no inhibitory effect on
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the suicide cleavage. This would also not be expected since the suicide cleavage
is  an  irreversible  reaction.  The  double  cleavage,  however,  was  significantly
Figure 8. The mutant Y723F htopoI can compete with the htopoI
double cleavage. Wt htopoI was incubated with L193s and mutant Y723F
htopoI as described in Experimental Procedures. A) Shows the influence of
mutant Y723F htopoI on the suicide cleavage of htopoI in an average from 3
to 5 experiments. B) Autoradiogram of a 14% sequence gel. Lane 1, no
htopoI, lane 2, 500 ng Y723F, lane 3, 500 ng htopoI, lanes 4 to 9, 500ng
htopoI and 250, 500, 1000, 2000, 4000 ng Y723F htopoI, and 4000 ng BSA
respectively C) Comparison of double cleavage „A“ from 3 to 5 experiments
as shown in B. A, b, and c represent the htopoI double cleavage as shown in
Figure 4.
inhibited by the titration with the active-site mutant (Figure 8B, compare lane 3
with lanes 4 to 8). With increasing concentrations of Y723F htopoI the double
cleavage was inhibited, however not completely. This is particular clear to see in
Figure 8C. As expected about 50% inhibition is seen when the ratio between wt
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and mutant htopoI is 1:1 (Figure 8C, 500ng Y723F htopoI). However, with
increasing concentration of the mutant enzyme a minimum is reached at about
40% residual  double cleavage activity. In Figure 5 the same degree of remaining
double cleavage was detected when the reactions were stopped with high salt
prior to protease digestion. This suggest that around 40% of the second cleavage
complex topoisomerases are not able to ligate. This may be caused by a release
of the suicide htopoI attached to the 13 nt long oligomer, thus making a ligation by
the second htopoI impossible.
4.8 Limited digest with subtilisin does not affect the suicide
cleavage, but eliminates the second cleavage step
The short distance from the suicidal cleavage site to the cleavage sites A, b, c,
and d suggests that the two htopoI molecules were in extreme proximity of each
other on the DNA substrate. Therefore, we wanted to investigate if protein
interactions between the two enzymes were possibly taking place. To investigate
this we performed a limited proteolysis of htopoI with subtilisin. Stewart et al.
(1996) published that limited proteolysis of htopoI with subtilisin removed the N-
terminal domain by specifically cleaving in the linker region so that the core and
the COOH-terminal domain were liberated, which however still remained
associated with each other and maintained catalytic activity. Later Ireton et al.
(2000) generated a mutant htopoI that lacked the N-terminal domain and parts of
the linker domain. After purifying this enzyme both monomers and dimers were
present. Based on these findings a model for the dimerization was set up and a
”domain swapping” interaction of the dimer was suggested. According to this
model the core domain of one enzyme binds to the C-terminal domain of the other
and vise versa. We therefore tested whether such a model could explain our
results. HtopoI was digested with subtilisin as described. The reaction was
followed by SDS-PAGE and Coomassie-staining (Figure 9A). A minor fraction of
htopoI was converted to a 80 kDa form (lanes 2 and 3) while the major fraction
existed as a 60  kDa fragment  (lanes  2 and  3, mobility  of  about  63kDa) (Figure
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Figure 9. Limited digest of baculovirus-expressed htopoI with
subtilisin. A) Coomassie staining of a 7.5% SDS-PAGE showing the partial
digest of htopoI by subtilisin. Two µg htopoI was incubated with 0, 20, 40, 60,
and 120 ng subtilisin for 20 min at room temperature and 800 ng htopoI of
each reaction was loaded in lanes 1 to 5 respectively. *, full length htopoI; §,
htopoI lacking the N-terminus; $, core domain lacking the N- and C-terminus;
M, 10 kDa protein ladder. B) Autoradiogram of a 7.5% SDS-PAGE. L193s was
incubated with: Load as in A. *, represents the shift caused by suicide
cleavage of full length htopoI; §, is caused by the suicide cleavage of htopoI
missing the N-terminus (80 kDa); #, is caused by the suicide cleavage of the
C-terminal domain and the core domain, however only the C-terminal domain
is covalently attached to the substrate. C) Autoradiogram of a 14%
sequencing gel. The same numbering is used as in B. D) The results from B
and C were quantified and depicted in a column chart. The numbering on the
X-axis represents the same as in B and C. Black bars represent the relative
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degree of suicide cleavage and quantify the results shown in B; gray bars
represent the relative degree of second cleavage site ”A” and quantify the
results shown in C. The results shown are representative for 3 independent
experiments.
9A). With increasing concentrations of subtilisin the 80 kDa form was completely
converted to the 60 kDa product (lane 4 and 5). From Stewart et al. (1996) it was
known that the 80 kDa fragment had lost the N-terminal domain while the 60 kDa
fragment had lost both the N- and C-terminal domain. The C-terminus ran out of
the gel as well as the fragments of the N-terminal domain. L193s was incubated
with these different digestion products and the amount of suicide cleavage was
detected. The bandshift caused by the suicide cleavage reaction changed
drastically after digestion with subtilisin (compare lanes 2 and 3 of Figure 9B). The
bandshift caused by undigested htopoI (marked with ”*”) is shown in lane 2. The
upper band in lane 3 represents the bandshift caused by the 80 kDa fragment
(marked with ”§”) which had a slightly faster mobility than the full length htopoI.
The lower migrating band (marked with ”#”) is due to the attachment of the
approximately 10 kDa C-terminal domain of htopoI (containing the active site
tyrosine) which associates with the 60 kDa fragment under native conditions. From
Figure 9B it can be concluded that the 60 kDa core domain and the 10 kDa C-
terminal domain retain enough activity to support an effective suicide cleavage
reaction although this was slightly less effective than that caused by the full length
enzyme. In Figure 9C the ability of these htopoI fragments to perform the double
cleavage reaction is shown. When comparing lane 2 with lane 3 a dramatic effect
can be seen. Despite the fact that the digested htopoI still retained the ability to
perform the suicide cleavage (Figure 9B, lanes 3 to 5) the ability to carry out the
double cleavage reaction was lost (Figure 9C, lanes 3 to 6). In Figure 9C lanes 3
and 4 a residual activity of the cleavage product A was still detectable, but this
was most likely caused by a small fraction of 80 kDa htopoI in these reactions.
The data from Figs. 9B and C are presented in a diagram form in Figure 9D.
Although the degraded forms of htopoI as shown in lanes 2 and 3 retained around
60% of the suicide cleavage activity the ability to perform the double cleavage
reaction was reduced to less than 10% or even totally lost. This indicates that a
protein-protein interaction is necessary for the double cleavage to occur and that
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the two htopoI enzymes may dimerize on the DNA mediated through the core and
C-terminal domain. When only the 80 kDa fragment was produced by subtilisin
digestion this had no effect on the suicide or double cleavage (data not shown).
The latter result rules out that the N-terminus was involved in the dimerization
reaction.
4.9 Midway status
Before going on with the second part of the thesis the results from the
aforementioned experiments are summarized in Figure 10. In Figures 4 and 5 it
         
Figure 10. Schematic representation of results. The htopoI double
cleavage complex arise after a stable cleavage complex (suicide topoI) has
formed. This is subsequently recognized by an additional htopoI molecule (A,
b, or c) which cleaves the DNA at the indicated distance to the other cleavage
site and a double cleavage complex is formed. The cleavage “d” is left out for
reason of simplicity.
was shown that immediately upstream from a htopoI cleavage complex additional
incisions took place. From Figure 6 it was found that these incisions occured
primarily 13 nts upstream from the cleavage complex, but also to a smaller extent
at distances of 11, 15, and 17 nts. It was shown in Figures 7 and 8 that these
incisions were done by additional htopoI molecules on DNA substrates which
contained htopoI cleavage complexes. In Figure 9 it was indicated that these
incisions, which are called „double cleavages“, may be mediated through protein-
protein interactions and therefore forming a complex (double cleavage complex).
Knowing all this it was now interesting to investigate if the tumor suppressor
protein p53 would be involved in this novel activity of htopoI, since p53 was shown
to regulate htopoI in vitro and in vivo (as described in paragraph 1.2.4).
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4.10 p53 stimulates the relaxation activity of htopoI in vitro
It was previously shown by Gobert et al. (1996 and 1999) and Albor et al. (1998)
that human and murine p53 stimulate the htopoI mediated relaxation of
supercoiled plasmid in vitro. As shown in Figure 11A these results were confirmed
and also show that there was a clear concentration dependent effect of the
stimulation by p53 (compare lane 2 with lanes 3 to 6). BSA showed no stimulatory
effect (lane 7) and the murine p53 preparation contained no detectable
topoisomerase I activity (lane 8). For this experiment very low amounts of htopoI
(1 and 3 ng) were used in order to see the stimulation clearly. If more htopoI was
Figure 11. Human wt, bovine wt, and murine His-p53 stimulate the
relaxation activity of htopoI equally well. A 0.8% agarose gel run in the
absence (- etbr) (A and B) or presence of 0.5 µg/ml ethidiumbromide (+ etbr)
(B). A) 3 ng htopoI was incubated with or without murine His-p53 for 5 min at
37°C. Lane 1, no htopoI, 2, htopoI, lane 3 to 7, htopoI and 50, 75, 140, 210 ng
mHisp53, and 210 ng BSA respectively, lane 8, 140 ng mHisp53. B) 1 ng
htopoI was incubated with or without 300 ng p53 for 5 min at 30°C. Lane 1, no
htopoI, 2, htopoI, lanes 3 to 5, htopoI and hp53, bp53, and mHisp53. r.,
relaxed, sc., supercoiled.
used the turn-over of the substrate was so fast that no stimulation could be
detected.
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Previously it was shown that human (Gobert et al. 1996 and 1999) or
murine p53 (Albor et al. 1998) could stimulate the activity of htopoI in vitro.
However, since it was of importance for the further investigations, p53 from three
different species were compared for their ability to stimulate htopoI activity in vitro.
Recombinant human, bovine, and murine His-p53 were tested and by comparing
lanes 3 to 5 (Figure 11B) it is seen that p53 from the three different species was
able to stimulate equally well. This shows that there is a high degree of
conservation for the ability to stimulate topoisomerase I activity among p53 from
the three species tested.
The similar behavior of p53 from different species may be due to the high
degree of conservation of the sequence sufficient for htopoI activation namely aa
302-320 for the human p53 (Gobert et al. 1999). Through a sequence homology
comparison it was found that this region had a high degree of homology. The
bovine p53 had 90% sequence identity and 95% sequence similarity and the
murine 70% identity and 85% similarity to the human p53 sequence in this region
(comparison was done using the alignment tool Clustal W;
www2.ebi.ac.uk/clustalw).
4.11 Murine His-p53 binds specifically to the core domain of
htopoI
As mentioned, Gobert et al. (1999) published that a p53 peptide was sufficient to
stimulate the activity of htopoI. However, it was not known which part of htopoI
bound to p53. We therefore performed a partial digest of htopoI using subtilisin
(Figure 12) and investigated by Far Western analysis to which domain of htopoI
p53 bound. The partial digest was performed under conditions where the N-
terminus was removed and the C-terminus and the core domain were separated,
as published by Stewart et al. (1996) (Figure 12A lane 2, 12B lane 1). The band
marked with an „a“ represents the full-length htopoI, „b“ the core domain, and the
fragment marked with „c“ represents the C-terminal part (Figure 12A and B).
When comparing the Coomassie stained gel with the Far-Western blot of Figure
12A a clear interaction between full-length htopoI and p53 can be detected (lane
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3) whereas no interaction with BSA was seen (lane 1). In lane 3 (Figure 12A)
degradation products of the N-terminus can be detected just below the full-length
band. This is frequently seen in a htopoI preparation since the N-terminus is highly
protease-sensitive.
Figure 12. p53 binds to the core domain of htopoI. A) 7.5% SDS-
PAGE. Far-Western and Coomassie staining as indicated Lane 1, BSA, lane
2, htopoI + 12 µg/ml subtilisin, lane 3, htopoI B) 13.75% SDS-PAGE Far-
Western and Coomassie staining as indicated. Lane 1, htopoI + 12 µg/ml
subtilisin, lane 2, htopoI. Far-Western was made with murine His-p53 in
solution. Detection was done by p53 antibody (Ab-7) and ECL detection as
described in Experimental Procedures. M, marker, a, full length htopoI, b, core
domain, c, C-terminal domain.
In Figure 12A lane 2 it is shown that this interaction was mediated solely through
the core domain of htopoI since the C-terminus showed no interaction (Figure 12B
lane 1) and the N-terminus was removed. Through N-terminal sequencing I found
that the core domain seen in Figure 12A lane 2 and Figure 12B lane 1 started at
Asp156. Far-Western analysis using human or bovine p53 also showed a clear
interaction with htopoI (data not shown). As a further control it was verified that the
p53 antibody did not bind unspecifically to htopoI (data not shown).
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4.12 Murine His-p53 stimulates the double cleavage activity of
htopoI in vitro
Since others and I have shown that p53 stimulates the activity of and forms a
physical complex with htopoI (as shown above) it was interesting to investigate if
p53 also was able to influence the htopoI double cleavage reaction. Thus, a
titration with murine His-p53 was performed in the presence or absence of CPT
and tested for any effect on the suicide or double cleavage. Figure 13A shows an
autoradiogram of a SDS-PAGE from which it can be seen that p53 had no
significant effect on the suicide cleavage with or without CPT (compare lane 3 with
lanes 4 to 8 and lane 12 with lanes 13 to 17). However, this was not the case
when the same reactions shown in Figure 13A were tested for the influence on the
second cleavage step. In Figure 13B a clear increase in the double cleavage by
htopoI was detected with increasing p53 concentrations (compare lane 3 with
lanes 4 to 8). From Figure 13B it can also be seen that addition of CPT showed an
additive effect in the presence of p53. This suggests that the mechanism by which
p53 stimulates the htopoI double cleavage reaction is different from the
stimulatory action of CPT. There are two possible ways for p53 to stimulate the
htopoI double cleavage: First, stimulation can be achieved by increasing the half-
life of each complex. This would be the same effect as it is the case with CPT (see
chapter 1.1.3). Thus, p53 would not be expected to have any significant effect in
the presence of CPT. Second, stimulation may occur by an increased formation of
the htopoI double cleavage complex. Here, it would be expected that an
incubation with p53 and CPT would result in an additive effect. Figure 13B (lanes
10 to 18) shows such an effect when p53 was titrated to htopoI in the presence of
CPT. When comparing lane 3 with lane 12 (Figure 13B) an about 2.5-fold effect of
CPT on htopoI alone can be detected. A 2.5-fold effect of CPT was also found in
the presence of p53 (Figure 13B, compare lane 7 with lane 16). The maximum
effect of p53 alone was approximately four fold (Figure 13B, compare lane 3 with
lane 7), however, when CPT was present as well their joined effect was
approximately 10 fold. BSA showed no effect in the presence or absence of CPT
(Figure 13B, compare lane 3 with lane 9 and lane 12 with lane 18). This strongly
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Figure 13. Murine His-p53 stimulates the double cleavage of htopoI.
A) Autoradiogram of a 7.5% SDS-PAGE showing the degree of suicide
cleaved substrate in the presence or absence of p53 and CPT as described in
Experimental Proceedures. Lane 1, no htopoI, lane 2, 800 ng murine His-p53,
lane 3, 400 ng htopoI, lanes 4 to 9, 400 ng htopoI and 100, 200, 400, 800,
1600 ng murine His-p53, and 1600 ng BSA respectively. Lanes 10 to 18 the
same as lanes 1 to 9 but in the presence of 10 µM CPT. B) Autoradiogram of
14% sequence gel. Lanes 1 to 18 as in A. C) Comparison of the influence of
murine His-p53 on the suicide cleavage from 3 to 5 experiments as shown in
Figure 13A. D) Comparison of the influence of mHisp53 on the htopoI double
cleavage from 3 to 5 experiments as shown in Figure 13B.
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indicates that the stimulatory effect of p53 and CPT are additive. Thus, the data
suggest that p53 stimulates the double cleavage by inducing the formation of
more double cleavage complexes without increasing their half-life. Figure 13C
shows a schematic representation of the influence of p53 on the suicide cleavage
and clearly shows that there was no significant effect. In Fig 13D the average
stimulation of the double cleavage A by p53 from three experiments is shown. p53
can stimulate the double cleavage by up to six fold, whereas BSA had no effect. It
can also be seen that an optimum was reached at around 800 ng p53, whereafter
the stimulation declined. This optimum was reached at a molar ratio of 1:4
between htopoI and p53 monomer. From previous studies it is known that p53
preferentially forms a tetramer (Stürzbecher et al. 1992; Friedman et al. 1992). So,
since a clear optimum was found when htopoI and the p53-tetramer were in a 1:1
ratio, this may indicate that tetrameric p53 is needed for an optimum stimulation.
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5 Discussion
The results presented in this dissertation have brought about new insights into the
possible roles of htopoI as well as of the tumor suppressor protein p53. Using a
htopoI suicide substrate in a novel design, it was shown that a htopoI cleavage
complex can attract an additional htopoI molecule to perform a nearby cleavage,
which here was called a htopoI double cleavage. The distance between the two
cleavage sites was estimated to be primarily 13 nts and to a smaller extent 11, 15,
or 17 nts. This additional cleavage was in part reversible as it could be inhibited up
to 60% by competion with the active site mutant Y723F htopoI. The small distance
between the two htopoI molecules gave rise to the speculation that the additional
cleavage could be mediated by direct protein-protein contacts. Through partial
digests with subtilisin a direct protein-protein interaction could be shown. Thus the
htopoI molecules formed an unstable complex on this substrate. This complex
was called a htopoI double cleavage complex. Data from the literature stating that
the tumor suppressor protein p53 can stimulate htopoI in vitro (Gobert et al. 1996,
Albor et al. 1998, Gobert et al. 1999) were confirmed. As a new finding, it was
directly shown that human, murine and bovine p53 stimulate htopoI equally well.
From the literature it is known that this stimulation is mediated by direct protein-
protein interactions (Gobert et al. 1996, Albor et al. 1998). In the present work it is
shown that p53 interacts with the core domain of htopoI. Finally it is shown that
the p53 tetramer specifically stimulates the formation of the htopoI double
cleavage complex in vitro.
In the following sections, a model and various scenarios will be presented
and discussed. These serve to explain the data summarized above, and to
suggest possibilities for possible physiological or pathological functions of these
complexes.
5.1 Model for htopoI double cleavage complex formation
This study demonstrates that recombinant htopoI expressed in S. cerevisiae or by
baculovirus is able to recognize a htopoI cleavage complex and cleave
predominantly 13 nts upstream from this complex (see Figure 10). This was
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shown by a strong sensitivity of the second cleavage step to CPT and by the fact
that it could be competed for by the active-site mutant Y723F htopoI but not by
BSA. The recognition of the cleavage complex is likely to be mediated by a dimer
formation between the two htopoI molecules on the DNA substrate as indicated by
the results shown in Figure 9.
In the literature one example showing that a mutant htopoI can form a
dimer has been previously reported. Ireton et al. (2000) observed that a mutant
htopoI (topo70∆L) missing the N-terminus and having a shortened linker domain
could form dimers in solution. This dimer eluted much later from a Mono S column
compared with the monomeric mutant htopoI. It retained full activity and the dimer
was even more active than the monomer. Furthermore, the mutant was more
sensitive towards CPT than was the monomer. Based on limited digestions of
htopoI70∆L with subtilisin a model was suggested according to which the C-
terminus of one enzyme can bind to the core of another enzyme and vice versa.
This phenomenon was called ”domain swapping”. It was suggested that this dimer
could form due to the shortened linker domain. This could affect the position of the
C-terminal domain with respect to the core domain. Thus, the interaction between
these two domains may be weakened considerably. This in turn could result in the
domain swapping mentioned above. Since it was found that the cleavage of the
linker region had a dramatic effect on the double cleavage reaction, but only a
minor influence on the suicide cleavage (see Figure 9), this indicates that for the
detection of the double cleavage it is essential that the core and C-terminal
domains are attached. This phenomenon could be explained by the following
model (Figure 14).
A htopoI enzyme binds and cleaves DNA suicidally. Thus, it is blocked in
the catalytic cycle and becomes ”frozen” in the cleavage conformation. This
conformation was shown by Stewart et al. (1996) to be different from the non-
bound state especially in the linker region which connects the core to the C-
terminal domain. It is therefore possible that the interaction between the C-
terminal and the core domains is less strong than that in the the non-bound state.
This may then open the possibility that the core domain of a second htopoI can
interact with the C-terminus of the ”frozen” htopoI and simultaneously cleave the
DNA, thereby  generating  the  second  cleavage  through  the  formation  of  an
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Figure 14. Model for htopoI double cleavage complex. See text for
further details.
unstable dimer. However, if the linker of htopoI is broken the second htopoI
enzyme may still cleave upstream of the ”frozen” htopoI and also ”swap” core
domains, but since the linker is broken there is no longer a protein contact that
holds the second htopoI in place. This can now religate and diffuse away. Thus,
the second cleavage reaction can no longer be detected. Although hypothetical,
this model is nevertheless supported by the direct protein-protein interactions
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presented in Figure 9, and by the very close proximity between the two cleavage
sites. The distance of 13 nts corresponds to approximately 44 Å. Redinbo et al.
(1998) and Stewart et al. (1998) published the crystal structure of a reconstituted
htopoI bound or complexed to DNA. They found that htopoI contacted DNA 4 bp
upstream and 6 bp downstream of the cleavage site in a htopoI recognition
sequence similar to the one used here. When bound to DNA htopoI covered 60 Å
along the DNA. Since the 44 Å we found is considerably less than the 60 Å
published for the crystal structure, not only direct protein-protein interactions
between the two adjacent htopoI molecules are highly likely, but also some
compaction is required possibly by domain swapping.
5.2 Could htopoI double cleavage complexes form in vivo?
The presence of htopoI dimers in vivo was recently suggested by Mao et al.
(2000). MCF-7 cells were irradiated with UV-light, and dimethyl suberimidate
(DMS) was subsequently added to the media in order to crosslink proteins. The
chromosomal DNA was then extracted, bound to a filter, and probed by antibodies
for htopoI that was bound covalently to the DNA. Using this technique the authors
found that there was a significant increase in the amount of htopoI bound
covalently to the UV irradiated DNA when DMS was added. This was interpreted
as a possible dimer formation between two htopoI molecules which occurred only
when the DNA was irradiated with UV light (Mao et al. 2000).
Lesions such as abasic sites, UV-photoproducts, and oxidative DNA
damage are preferentially bound by htopoI and all these lesions lead to a
stabilization of the enzyme in the cleaved state (Lanza et al.1996, Mao et al. 2000,
Subramanian et al. 1998, Pourquier et al. 1999). This situation is mimicked by our
suicide substrate. Thus, a recognition of the ”frozen” htopoI as proposed for our in
vitro system may also be true for htopoI ”frozen” in vivo in the vicinity of the kinds
of DNA damage mentioned above. Such a mechanism would also ensure that a
htopoI double cleavage complex does not form in the absence of damage, since
the cleaved state during a normal catalytic cycle of htopoI would be too short-lived
to be recognized by another htopoI molecule. I have also found that htopoI double
cleavage complexes could be observed when suicide substrate and recombinant
htopoI were added to whole cell extracts. The double cleavage reaction was even
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stimulated up to 4-fold (data not shown). This was done under reaction conditions
where the added recombinant htopoI made up only 0.3% of the total protein mass
in the reaction mixture. This has not yet been investigated further. However, it
does support the assumption that htopoI double cleavage complexes also can
form in vivo.
5.3 Repair through recombination?
When a htopoI enzyme recognizes a DNA lesion and forms a cleavage complex, it
is in principle able to perform the religation step and diffuse away. However,
religation and diffusion are much slower on damaged DNA. The cleavage complex
may also be converted into an irreversible lesion (Tsao et al. 1993, Wu an Liu
1997) which effectively blocks transcription and replication. Several groups have
searched for a mechanism that would repair such a lesion (Yang et al. 1996,
Sastry and Ross 1998, Pouliot et al. 1999, Pouliot et al. 2001, Interthal et al.
2001), but up to now little is known about how such lesions are removed in human
cells.
Several groups have shown that htopoI may be involved in recombination
events. Recombination in vitro by eukaryotic topoI was shown by Shuman (1992),
Christiansen and Westergaard (1994), as well as Pourquier et al. (1997a). They
found that topoI, when stabilized in a covalent cleavage complex, was able to
accept a 5’-OH from a foreign DNA strand, that could hybridize downstream from
the cleavage complex. This was supported by a study which compared eukaryotic
topoI to known recombinases. Cheng et al. (1998) found that eukaryotic topoI was
not related to recombinases such as the Cre-recombinase family in their amino
acid sequence but upon comparing the structures they found that there were great
similarities in the catalytic domains of these enzymes. They also share common
mechanistical features, namely that they both form covalent complexes with the
3'-end of the DNA. By sequencing known recombination sites and looking for
preferred topoI cleavage sites it was found by Zhu and Schiestl (1996) that, when
topoI was overexpressed in Saccharomyces cereviciae, increased recombination
was observed. The sites of recombination were sequenced and it was found that
60% of these sites contained preferred topoI cleavage sites immediately 5’ to the
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recombination site. Some viruses, which need recombination events either to
integrate into the host genome or to form closed circular viral DNA, have been
found to involve topoI at least in vitro (Wang and Rogler 1991, Pourquier et al.
1999). Finally, the most convincing evidence for the involvement of topoI cleavage
complexes in recombination was published by Megonigal et al. (1997). They had
generated a topoI mutant in yeast which could ligate, but much more slowly than
the wt enzyme. When expressing this enzyme in yeast they found that at high
levels of expression it was lethal, but when expressed at sub-lethal levels it gave
rise to a great increase in rDNA recombination.
All of the aforementioned results strongly suggest that htopoI could be
involved in DNA recombination in vivo. It is thus tempting to speculate that
formation of an unstable htopoI double cleavage complex could be the initiation of
a repair event via recombination where the second htopoI enzyme is used as a
ligase.
What could such a repair pathway look like? In Figure 5 and 8 it was found
that approximately 40% of the cleavages could not be reversed by addition of high
salt or by mutant htopoI. These 40% may very well represent double cleavages
where the first cleavage complex (suicide complex) was released, since the weak
protein-protein interactions could no longer hold the suicide htopoI with the
attached oligomer in place. Once it has diffused away it makes a reversal of the
second cleavage impossible. In this situation a gap is formed which may permit a
5’-OH containing DNA strand to hybridize and start a homologous recombination
event using the htopoI molecule as a ligase. This scenario is shown in Figure 15.
A htopoI cleaves in the vicinity of a DNA lesion and is frozen in the cleavage
confirmation (damage recog. htopoI, red). A „repair“ htopoI (green) recognizes this
complex through a protein-protein interaction, and cleaves just upstream of it. The
large damage recognition htopoI is bound to a very short DNA fragment. When
also taking the rather weak protein-protein interactions into consideration, it could
be released and thereby leave a gap in front of the repair htopoI which is now
trapped. Now, a foreign 5’-OH containing DNA strand could enter and hybridize to
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Figure 15. Hypothetical recombination repair of htopoI cleavage
complexes. A DNA lesion is shown with a purple cross. The incoming foreign
DNA strand is marked in thick blue to distinguish it from the original strand.
See text for further details.
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the gap. Then a strand transfer reaction could take place where the DNA strand
containing the damage is completely or partly released. This would also ensure
the removal of the original DNA lesion. The repair htopoI could then function as a
ligase and thereby release itself from the DNA. A gap resulting in this way could
subsequently be filled up by DNA replication.
The scenario described above is presently being tested in a Masters
degree project. Data from this project confirm that the „repair“ htopoI can indeed
ligate a foreign DNA strand which can hybridize to the predicted gap, thus
confirming the scheme suggested above.
5.4 The tumor suppressor protein p53 interacts with the core
domain of htopoI
We have shown that human, bovine, as well as murine p53 stimulate the
relaxation activity of htopoI equally well (Figure 11). In addition it was shown
through limited digests of htopoI with subtilisin and subsequent Far-Western
analysis using p53 in solution that p53 interacts solely with the core domain of
htopoI (Figure 12). The core domain is responsible for binding the DNA and
undergoes conformational changes when binding and cleaving the DNA,
especially within the active site (Redinbo et al. 1998, Stewart et al. 1998). Since
p53 was found to interact with this domain it may also explain why the activity of
htopoI is dramatically increased upon binding of p53. It is possible that p53
induces conformational changes within the core domain which causes the enzyme
to increase its catalytic activity. However, what the more precise mechanism for
the stimulation is and with which part of the core domain the interaction takes
place needs further investigation. Investigations are going on in our laboratory to
answer these questions. The strong direct interaction between htopoI and p53
makes it very interesting to investigate what role this interaction could play in the
cell. This is discussed in detail in the next chapter.
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5.5 Could htopoI function as a p53-dependent switch between
repair and apoptosis?
As shown in Figures 12 and 13 it was not only found that p53 interacts with the
core domain of htopoI, but also that it has a significant stimulatory effect on the
formation of double cleavage complexes. p53 stimulated complex formation on
average by a factor of six. p53 mainly exists as a tetramer in solution (Stürzbecher
et al. 1992, Friedman et al. 1992). In agreement with this it was observed here
that the optimum for p53 stimulation was achieved when htopoI and p53 monomer
were in a molar ratio of 1:4 respectively (Figure 13). Since complex formation
between p53 and htopoI could be demonstrated (see Figure 12), it is highly likely
that this stimulation was mediated by direct interactions of p53 with htopoI and not
by interactions mediated by the DNA. By investigating the effect of CPT with or
without p53 it was found that CPT and p53 had additive effects (Figure 13). Since
CPT efficiently stabilizes htopoI cleavage complexes, it would be expected that
p53 would not be able to further stimulate complex formation if it also stabilized
the double cleavage complex. It was therefore more likely that p53 did not
stabilize the double cleavage complexes, but rather stimulated complex formation
by for instance increasing the affinity.
However, could this observation have any significance in vivo? Based on all
of the results presented here and those from the literature, I propose that this
might very well be the case. Since p53 has been found to be involved in DNA
repair and apoptosis, and since the lethality of CPT induced htopoI cleavage
complexes depend on p53 (Yang et al. 1996b, Li et al. 1998), it is tempting to
speculate that p53 and htopoI may help to decide between DNA repair and
apoptosis after genotoxic stress. This is shown in Figure 16.
When a cell is exposed to endogenous or exogenous DNA damaging
agents DNA lesions are formed and the p53 level is up-regulated in response to it
(see chapter 1.3.1). Once up-regulated, p53 could activate htopoI to form
cleavage complexes in the vicinity of DNA lesions. If present in abundance, these
bulky complexes could induce apoptosis (discussed in detail later). If, however,
only a few cleavage complexes have formed, these could signal that the damage
level is low and that repair should be initiated. The lesions could then be repaired
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Figure 16. Suggested “switch”-function of p53 and htopoI between
repair and apoptosis. The cell is damaged by for example UV light. The
resulting lesions are represented by red circles. HtopoI is shown as yellow
circles. The incoming strand in recombination is shown in blue. See text for
further details.
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by the characterized repair mechanisms such as NER, base excision repair, and
mismatch repair. However, the htopoI cleavage complex must also be removed.
This could be done by the recombination repair suggested above (Figure 15).
Once all lesions are removed, p53 is no longer up-regulated and the cell may
enter the cell cycle again.
Subramanian et al. (1998) presented a model, which suggested that htopoI
form cleavage complexes at DNA lesions, because it is directly involved in the
repair of the lesion. They suggested this on the basis of investigations where they
found for the first time that htopoI formed cleavage complexes on UV damaged
DNA in vivo. The complex formation was reduced in XP-A cells and not above
background level in XP-D cells. XP-A cells carry mutations in the XPA protein,
which is involved in damage recognition in NER. XP-D cells carry mutations in the
XPD protein, which is a 5’ to 3’ helicase involved in NER. Both cell lines are highly
sensitive to UV-irradiation. Based on these results they suggested a model in
which htopoI is directly involved in the repair of the lesion possibly by relieving
tension in the DNA around the lesion. However, this would imply that htopoI
cleavage complexes should form at every lesion and this is unlikely to happen.
Jones et al. (1991), Frosina and Rossi (1992), Stevnsner and Bohr (1993), and
Thielman et al. (1993) all found that CPT had no or only a weak negative influence
on NER in vitro and in vivo. This either suggests that there is no significant role of
htopoI in NER either in vitro or in vivo or that in up to 18% of the cases (Jones et
al. 1991, Thielman et al. 1993) a htopoI cleavage complex is located so close to a
lesion that it hampers its recognition/repair (Frosina and Rossi 1992). This is
further supported by the fact that BER as well as NER can be reconstituted in vitro
with purified proteins without the addition of htopoI (Aboussekhra et al. 1995,
Kubota et al. 1996). I therefore do not find the model presented by Subramanian
et al. (1998) convincing. Rather, I find it more likely that a small fraction of the
lesions are recognized by htopoI in a p53-dependent manner and that if these
complexes exceed a threshold, p53-dependent apoptosis is induced in a similar
fashion to cancer cells treated with CPT (Yang et al. 1996b, Li et al. 1998). When
few htopoI cleavage complexes form, these may be removed by the formation of a
double cleavage complex as suggested above (Figure 16).
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How could such a repair through recombination take place? Rad51 has been
shown to be an important factor for homologous recombination. It is homologous
to the E. coli RecA, which builds nucleoprotein filaments on ss-DNA and searches
for homologous sequences (reviewed by Shinohara and Ogawa 1999). p53 has
been found to interact with Rad51 in vitro as well as in vivo. Through this
interaction p53 was found to inhibit Rad51 mediated recombination (Stürzbecher
et al. 1996). However, this interaction could be released by the SV40 T-antigen,
which also interacts with p53, and thereby reactivated Rad51. It was speculated
that this could ensure that Rad51 only would initiate recombination events when
needed and that p53 would function as a regulator of recombination through
Rad51 (Stürzbecher et al. 1996). What is presented in Figure 16 also implies
homologous recombination. Hence, Rad51 also may play a role in such a putative
recombination reaction. Thus, it could be speculated that p53 (bound to Rad51)
binds to htopoI following DNA damage and induces the formation of htopoI double
cleavage complexes. Thereby it releases Rad51 and Rad51 can participate in
repair through recombination as suggested in Figures 15 and 16.
In Figure 16 it was suggested that many htopoI cleavage complexes lead to
p53 dependent apoptosis. However, it remains puzzling how p53 induces cell
death (see chapter 1.3.3). It was recently published that the multifunctional protein
Ref-1 plays an important role in the p53-dependent cell cycle arrest after CPT
treatment. Furthermore, it was found that Ref-1 was important in p53-dependent
apoptosis (Gaiddon et al. 1999). This was concluded since antisense Ref-1 mRNA
lowered the sensitivity to CPT treatment by 2.5 fold in vivo. It is therefore possible
that Ref-1 is involved in the p53-dependent induction of apoptosis in the presence
of htopoI cleavage complexes.
When discussing the induction of apoptosis as presented in Figure 16 it
may be important to distinguish between htopoI bound p53 and non-bound p53.
As suggested in Figure 16 p53 is induced/activated after DNA damage. This could
be facilitated through N-terminal phosphorylation of p53 by the ATM gene product
(Siliciano et al. 1997, Banin et al. 1998,), which prevents MDM2 dependent
degradation of p53. This induction of the p53 level may only be limited and serve
to activate htopoI cleavages at DNA lesions. The p53 associated htopoI
complexes could, however, initiate a stronger damage signal than for example a
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pyrimidine dimer alone. Such a bulky lesion may be recognized better than a small
pyrimidine dimer by proteins such as the ATM gene product and/or DNA
dependent protein kinase (DNA-PK). These in turn may cause a further release of
MDM2 bound p53 in a feedback loop. This newly released p53 may in turn
activate genes such as BAX and p21WAF1 dependening on the amount of p53
released from MDM2. In the case of small amounts, p53 may induce transcription
of genes such as p21WAF1 to allow repair. If a large amount of p53 is released from
MDM2, genes involved in apoptosis, such as BAX, may be activated. In
agreement with this Jaks et al. (2001) found that when few htopoI cleavage
complexes were induced by CPT transcriptional activation of p21WAF1 took place,
but no cell cycle arrest or apoptosis. Only when more htopoI cleavage complexes
were introduced this also led to cell cycle arrest.
As suggested above DNA-PK could sense the htopoI cleavage complex and
thereby activate a p53 dependent response. p53 and the replication protein A
(RPA) have been found to form a complex (Li and Botchan 1993, Dutta et al.
1993). Abramova et al. (1997) observed that when cells are UV-irradiated this
complex is disrupted. The release of p53 from RPA was found to be essential for
activation of DNA repair. Later Shao et al. (1999) found that when human cells
were treated with CPT RPA was phosphorylated by DNA-PK. Kohn et al. (2000)
suggested a model where RPA becomes phosphorylated by DNA-PK after DNA
damage and this causes the release of p53 which in turn can activate downstream
pathways. It has been suggested that ATM could be an alternative to DNA-PK as
the sensor of p53 induced htopoI cleavage complexes. Piret et al. (1999) found
that the ATM gene product was essential for the response to CPT treatment. This
indicates that ATM participates in a pathway which senses the level of htopoI
cleavage complexes
In conclusion the possibilities discussed above suggest that factors such as
Ref-1, ATM, and DNA-PK can play important roles in sensing the p53 induced
htopoI cleavage complexes and to induce p53 dependent DNA repair or
apoptosis.
In the above a possible role for p53 induced htopoI cleavage complexes in
apoptosis or repair was discussed, and also how the htopoI cleavage complexes
could be removed by recombination through the formation of a htopoI double
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cleavage complex. It is, however, also possible that there may exist alternative
repair pathways for removal of htopoI cleavage complexes in human cells. Nash
and co workers (Yang et al. 1996, Pouliot et al. 1999, Pouliot et al. 2001) have
identified an enzyme in Saccharomyces cereviciae, which they named Tdp1. Tdp1
can cleave a htopoI cleavage complex at the bond between Tyr723 and the DNA
backbone. A human Tdp1 homologue has been identified and cloned (Interthal et
al. 2001). Tdp1 can only remove the covalently linked topoI enzyme if the intact
topoI is digested by a protease which leaves a small peptide rest covalently
attached to the DNA. However, Tdp1 is very inefficient when this peptide rest is
situated on double stranded DNA. Pouliot et al. (2001) found when a topoI peptide
was located at a blunt end Tdp1 efficiently removed the peptide rest. They
therefore suggested that Tdp1 cannot repair topoI cleavage complexes on intact
DNA, but only when double-strand breaks, due to DNA replication, have been
produced. That Tdp1 most likely is involved in repair of topoI cleavage complexes
in yeast was found in knockout studies (Pouliot et al. 1999 and 2001). A role of the
human TDP1 gene has not yet been shown. The knocking out of the TDP1 gene
in yeast resulted in an increased sensitivity to CPT. However, this increase was
small, and therefore indicates that there must be alternative pathways.
Pouliot et al. (1999 and 2001) found that a Rad9-dependent pathway
seemed more important than the Tdp1 pathway. Rad9 is a kinase involved in a
checkpoint response pathway in yeast. After DNA damage Rad9 associates with
Mec1 (another kinase) at a DNA lesion. Once this complex has formed, Mec1
phosphorylates Rad9 and the complex dissociates. In return Rad9 phosphorylates
Rad53 (another kinase) (Gilbert et al. 2001). Rad53 activates pathways, which
lead to cell cycle arrest and allow DNA repair (Pellicioli et al. 1999, Neecke et al.
1999).
The Rad9 dependent repair pathway suggested by Pouliot et al. (2001) could
be the functional analog to the p53-dependent repair pathway discussed here
since there are significant similarities. p53 is activated after DNA damage through
phosphorylation, as it also is the case of Rad9 and Rad53. The phosphorylation of
p53 is also mediated by a “damage-sensor” such as ATM, which could be the
equivalent to the Mec1 kinase. Furthermore, the activation of both p53 and Rad53
lead to activation of a cell cycle arrest or apoptosis. If these pathways truly are
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analogues it could mean that the scenario suggested in Figure 16 is an alternative
to a possible Tdp1-dependent repair pathway.
5.6 Can htopoI double cleavage formation in part explain
genomic instability in cells with mutated p53?
p53 exists in a mutant form in about 50% of all tumors (as mentioned previously).
All of these mutations lead to a loss of wild-type activity, but some also result in a
so-called “gain of function”. Gain of function describes p53 mutations that still
retain some p53 activities, although the transactivation role has been lost. This
means that they can still bind to various protein factors and are also up-regulated,
but fail to induce cell cycle arrest or apoptosis due to the inactivation of the DNA
binding domain. If p53 mutations are located on one allele, it can be speculated
that enough wt p53 tetramers could form to retain a normal p53 response.
However, it has been found that mutant p53 can interact with wt p53 to form
tetramers in a dominant-negative fashion. Through this complex formation the wt
p53 is influenced by the mutant p53 in such a way that wt activity is lost. Such
cells show genomic instability, exemplified by increased recombination events
(Mekeel et al. 1997, reviewed by Murphy and Rosen 2000, Albor and Kulesz-
Martin 2000). p53 mutants have been found to show “gain of function” activities
concerning stimulation of htopoI. Gobert et al. (1999) showed that a p53 mutant
(R273H) was constantly associated with and stimulated htopoI in vivo, whereas wt
p53 only stimulated in a brief period following cellular stress. In addition, Albor et
al. (1998) found that two other p53 mutants N239S and R245S also could
stimulate htopoI in vitro. These mutants have lost their ability to induce cell cycle
arrest/apoptosis, but still retain their htopoI stimulating activity. Therefore, with the
model suggested above it can be predicted that in a cell with such mutant p53,
DNA damage such as UV irradiation could lead to genomic instability. This could
be due to the loss of the regulatory function of p53 in such cells (Cao et al. 1997;
Sigal and Rotter 2000) and therefore the htopoI mediated recombination events
(see Figures 15 and 16) therefore could go out of control and lead to cancer as
suggested by Albor and Kulesz-Martin (2000).
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5.7 Future perspectives
The results presented above are part of a relatively new advancement in the
investigations on the role of p53 and htopoI in cancer development, DNA repair,
and apoptosis. At present there are only few publications on this issue, but it is
receiving increasing attention in recent reviews (e.g. Albor and Kulesz-Martin
(2000) and Kohn et al. (2000)). This field opens up new possibilities to learn more
about how p53 can function as a tumor suppressor and in mutated form as a
promoter of cancer. In this context it could therefore be fruitful to follow up the
ideas presented in Figure 15 and 16.
As mentioned previously there are current investigations in our laboratory
showing that the recombination model presented in Figure 15 indeed does take
place in vitro. These investigations will also include studies on the influence of p53
on this observed htopoI-mediated recombination in vitro. These are important
investigations since they could shed more light on the question whether this
observed recombination could be a p53 regulated repair pathway. This pathway,
however, can go out of control in cells with “gain of function” p53 mutants and
cause genomic instability.
At present, experiments have just started in our laboratory to investigate
whether htopoI double cleavage complexes also form in vivo. Furthermore, we are
trying to verify whether the model suggested in Figure 16 is correct. For both
purposes a so called ICT assay will be used which can detect the formation of
htopoI cleavage complexes on DNA in vivo. The method was first published by
Subramanian et al. (1998). In this assay cells are treated with UV light or other
DNA damaging agents. Subsequently at different time points after introduction of
damage the DNA is extracted and the protein denatured in order to trap htopoI
cleavage complexes on the DNA. Western-blotting is used to detect the htopoI
signal on the DNA. It is hoped that this technique can be used to confirm the
hypothetical pathway presented in Figure 16. Cells will be exposed to various
intensities of UV-C irradiation and allowed to recover for various periods of time.
Using the ICT-assay the occurrence of htopoI cleavage complexes can be
detected. At low UV-C dosage it would be expected that the cleavage complexes
will disappear in time due to repair. However, at high exposures the scenario
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presented in Figure 16 would  predict that the cleavage complexes would be
persistant. Simultaniously the degree of apotosis will be tested at various
timepoints and irradiation intensities. In this way it may be possible to show a
correlation between the occurrence of htopoI cleavage complexes and the onset
of apoptosis. This would then suggest that the persistancy of htopoI cleavage
complexes correlate with apoptosis and thereby support the in Figure 16
presented scenario. By using different cell-lines with various p53 status the
possible coordinated action of p53 and htopoI in this putative process could be
investigated.
Furthermore it will be investigated if htopoI double cleavage complexes
form in vivo. The ICT assay will for this pupose be modified slightly. Various cell
lines will be exposed to UV-C irradiation and allowed to recover for various periods
of time. Subsequently, the cells will be treated with a protein-protein croslinker
(dimethyl suberimate) and lyzed. The DNA is blotted and Western-blot analysis
performed. If a stronger htopoI signal is evident after treatment with the
crosslinker, it would suggest that htopoI double cleavage complexes also form in
vivo. Such a result would confirm the data of Mao et al. (2000). I will try to extend
these data by investigating the putative htopoI complexes formation under various
conditions. In parallel to this investigation the crosslinking of p53 to htopoI will also
be investigated. I especially wish to test under what conditions p53 forms a
complex with htopoI. In this respect it is of particular interest to investigate if the
interaction with htopoI in a cell line with mutant p53 shows another pattern than it
is the case in a cell line with wt p53. In particular this would serve to support the
assumption that the association between htopoI and mutant p53 could lead to
genomic instability as discussed in chapter 5.6.
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6 Summary
HtopoI is an essential enzyme in higher eukaryotes. It has been shown to be
involved in transcription, replication as well as in recombination. Recently a
substantial number of publications have shown that htopoI can cleave in the
vicinity of various DNA lesions and thereby form cleavage complexes. This has
been demonstrated in vitro as well as in vivo. HtopoI cleavage complexes have
been shown to be lethal in cancer cells when induced by the chemotherapeutic
agent CPT and its analogs. It was therefore highly interesting to investigate which
function the induction of htopoI cleavage complexes on damaged DNA may play.
In the literature it was suggested that these complexes might be involved in a
repair of the DNA lesions. However, in the major part of the literature it seems to
become more and more accepted that these cleavage complexes should rather
be regarded as bulky lesions. Therefore it has been attempted to find out how
such complexes can be repaired in the cell. However, there is at present no clear
picture of how this occurs in human cells. The present thesis deals with this topic.
In the present thesis this issue was investigated by the use of a novel
suicide substrate. Such substrates trap a htopoI cleavage complex irreversibly at
one position on the substrate. Using this substrate with a radioactive label at
position 15 from the 3’ end it was found that in vitro an additional htopoI molecule,
could recognize a stable suicide cleavage complex through protein-protein
interactions. The distance between the two cleavage sites was estimated to be
primarily 13 nts, but with minor cleavage sites at distances of 11, 15, and 17 nts
as well. The interaction was found to be fairly unstable since the active site mutant
htopoI could compete with wt molecules for the interaction. This complex was
called a htopoI double cleavage complex. From the literature it is known that the
tumor suppressor protein p53 interacts with and stimulates the activity of htopoI in
vitro as well as in vivo. In the present thesis it was shown, that this interaction was
mediated through the core domain of htopoI. This was found by Far-Western
analysis where the domains of htopoI were separated through partial digests by
subtilisin. In vitro the interaction between htopoI and p53 was found to stimulate
the formation of double cleavage complexes about six-fold by an as yet
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unidentified mechanism. It was however found that p53 most likely stimulates the
formation of the double cleavage complexes and not the stability of the complex.
Since htopoI cleavage complexes also form in vivo at DNA lesions a model
is proposed that is based on the results presented here and data from the
literature. It suggests that the double cleavage complex formation could be the
first step in a repair of the htopoI cleavage complex through a p53-dependent
recombination pathway. This however would only take place if few cleavage
complexes have formed. If high amounts of complexes exist this could lead to
apoptosis. It is also speculated that this could help to explain the phenotype of
genomic instability observed in several p53 mutant cells.
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7 Zusammenfassung
HTopoI ist ein essentielles Enzym in höheren Eukaryoten für das es eine
Beteiligung an der Transkription, Replikation und Rekombination nachgewiesen
worden ist. Zahlreiche aktuelle Publikationen zeigen, dass hTopoI in der Nähe von
verschiedenen DNA-Schäden schneidet und so einen kovalenten Schnittkomplex
bildet. Dies wird sowohl in vitro als auch in vivo gefunden. Die von dem
Chemotherapeutikum CPT und seinen Derivaten hervorgerufene hTopoI-
Schnittkomplexe sind für Tumorzellen letal. Aus diesem Grund war es von
Interesse, die Funktion des hTopoI-Schnittkomplexes auf geschädigter DNA zu
klären.
In der Literatur wird vorgeschlagen, dass hTopoI-Schnittkomplexe eine
Mitwirkung der hTopoI an der DNA-Reparatur repräsentieren könnten. In der
Mehrheit der Publikationen setzt sich aber die Meinung durch, dass der hTopoI-
Schnittkomplex als ein großes DNA-Schadensereignis gelten kann. Aus diesem
Grunde gibt es Bemühungen, die möglichen Wege, die eine Zelle zur Reparatur
solcher DNA-Schäden einschlagen kann, aufzuklären. Zur Zeit existiert bezüglich
humaner Zellen auf diese Fragestellung noch keine klare Antwort.
Diese Fragestellung wurde in der vorliegenden Arbeit, mittels eines neu
konstruierten Suizidsubstrats, untersucht. Solche Substrate „fangen“ hTopoI-
Schnittkomplexe irreversibel an einer Position ein. Mit einem an Position 15 vom
3‘ Ende radioaktiv markierten Suizidsubstrat konnte in vitro gezeigt werden, dass
ein stabiler Schnittkomplex von einem zweiten hTopoI Molekül mittels Protein-
Protein Interaktionen erkannt werden kann. Der Abstand zwischen den beiden
Schnittstellen wurde überwiegend auf 13, seltener auch auf 11, 15 und 17
Nukleotide gemessen. Die Interaktion war relativ instabil, da eine Mutante des
aktiven Zentrums von hTopoI die Interaktion zwischen den beiden Wildtyp
Enzymen austitrieren konnte. Dieser Komplex wurde im Folgenden als ein
Doppel-Schnittkomplex bezeichnet.
In der Literatur wurde beschrieben, dass das Tumorsuppressor Protein p53
mit hTopoI interagiert und so die Aktivität von HtopoI in vitro und in vivo stimuliert.
In dieser Arbeit konnte gezeigt werden, dass die Interaktion von der core-Domäne
der hTopoI vermittelt wird. Dies wurde mit einem Far-Western Verfahren
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nachgewiesen, wobei die Domänen der hTopoI durch einem partiellen Verdau mit
Subtilisin voneinander getrennt wurden. Die Interaktion zwischen hTopoI und p53
stimulierte mittels eines unbekannten Mechanismus den hTopoI-Doppel-
Schnittkomplex in vitro um das 6-fache. Dabei stimuliert p53 wahrscheinlich die
Bildung eines solchen Komplexes und erhöht nicht dessen Stabilität.
Da hTopoI-Schnittkomplexe, wie bereits erwähnt, auch in vivo an
geschädigter DNA gefunden werden, wurde unter Berücksichtigung der hier
präsentierten Ergebnisse und der Literatur dieses Fachgebiets ein Model
entwickelt. Dies beschreibt die Bildung eines Doppel-Schnittkomplexes als ersten
Schritt in einer vom hTopoI-Schnittkomplex ausgeführten DNA-Reparatur, die
außerdem einen p53-abhängigen Rekombinationsweg umfasst. Dieser Vorgang
würde aber nur ablaufen, wenn relativ sich wenige Komplexe bilden; die Bildung
vieler Komplexe würde zur Apoptose führen. Abschließend wird spekuliert, dass
dies möglicherweise den bei vielen Zellen mit mutiertem p53 auftretenden
Phänotyp der genomischen Instabilität erklären könnte.
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